<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2009211069
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2016
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        TECFIDERA 240 mg capsule
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        Dimethyl Fumarate
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        240
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Capsule
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        56
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        48
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        do not store above 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        4558.15
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="CORDEN PHARMA FRIBOURG AG" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            CORDEN PHARMA FRIBOURG AG
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 530]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Salehiya Trading Co.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Biogen Idec B.V-Natherland
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N07XX09
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>&nbsp;</strong></p><p><strong>What Tecfidera is</strong></p><p>&nbsp;</p><p>Tecfidera is a medicine that contains the active substance <strong>dimethyl fumarate</strong>.</p><p>&nbsp;</p><p><strong>What Tecfidera is used for</strong></p><p><strong>&nbsp;</strong></p><p><strong>Tecfidera is used to treat relapsing remitting multiple sclerosis (MS) in patients aged 13 years and older</strong>.</p><p>&nbsp;</p><p>MS is a long-term condition that affects the central nervous system (CNS), including the brain and the spinal cord. Relapsing remitting MS is characterised by repeated attacks (relapses) of nervous system symptoms. Symptoms vary from patient to patient, but typically include walking difficulties, feeling off balance and visual difficulties (e.g. blurred or double vision). These symptoms may disappear completely when the relapse is over, but some problems may remain.</p><p><strong>&nbsp;</strong></p><p><strong>How Tecfidera works</strong></p><p>&nbsp;</p><p>Tecfidera seems to work by stopping the body&rsquo;s defence system from damaging your brain and spinal cord. This may also help to delay future worsening of your MS.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>&nbsp;&nbsp;</strong></p><p><strong>Do not take Tecfidera</strong></p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>if you are allergic to dimethyl fumarate</strong> or any of the other ingredients of this medicine (listed in section 6).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>if you are suspected to suffer from a rare brain infection called progressive multifocal leukoencephalopathy (PML) or if PML has been confirmed.</strong></p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p><strong>&nbsp;</strong></p><p>Tecfidera may affect your <strong>white blood cell counts</strong>, your<strong> kidneys </strong>and<strong> liver</strong>. Before you start Tecfidera, your doctor will do a blood test to count the number of your white blood cells and will check that your kidneys and liver are working properly. Your doctor will test these periodically during treatment. If your number of white blood cells decreases during treatment, your doctor may consider additional analytic measures or discontinue<em> </em>your treatment.</p><p><strong>&nbsp;</strong></p><p><strong>Talk to your doctor</strong> before taking Tecfidera if you have:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe <strong>kidney</strong> disease</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe <strong>liver</strong> disease</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a disease of the <strong>stomach</strong> or <strong>bowel</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a serious<strong> infection </strong>(such as pneumonia)</p><p>&nbsp;</p><p>Herpes zoster (shingles) may occur with Tecfidera treatment.&nbsp; In some cases, serious complications have occurred. <strong>You should inform your doctor</strong> immediately if you suspect you have any symptoms of shingles.</p><p>&nbsp;</p><p>If you believe your MS is getting worse (e.g. weakness or visual changes) or if you notice any new symptoms, talk to your doctor straight away because these may be the symptoms of a rare brain infection called progressive multifocal leukoencephalopathy (PML). PML is a serious condition that may lead to severe disability or death.</p><p>&nbsp;</p><p>A rare but serious kidney disorder (Fanconi Syndrome) has been reported for a medicine containing dimethyl fumarate, in combination with other fumaric acid esters, used to treat psoriasis (a skin disease). If you notice you are passing more urine, are more thirsty and drinking more than normal, your muscles seem weaker, you break a bone, or just have aches and pains, talk to your doctor as soon as possible so that this can be investigated further.</p><p>&nbsp;</p><p><strong>Children and adolescents</strong></p><p>&nbsp;</p><p>The warnings and precautions listed above also apply to children. Tecfidera can be used in children and adolescents aged 13 years and above. No data are available in children below 10 years of age.</p><p><strong>&nbsp;</strong></p><p><strong>Other medicines and Tecfidera</strong></p><p>&nbsp;</p><p><strong>Tell your doctor or pharmacist</strong> if you are taking, have recently taken or might take any medicines, in particular:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines that contain <strong>fumaric acid esters</strong> (fumarates) used to treat psoriasis</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>medicines that affect the body&rsquo;s immune system </strong>including <strong>other medicines used to treat MS</strong>, such as fingolimod, natalizumab, teriflunomide, alemtuzumab, ocrelizumab or cladribine, or some commonly used <strong>cancer</strong> treatments (rituximab or mitoxantrone).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>medicines that affect the kidneys including </strong>some <strong>antibiotics</strong> (used to treat infections), &ldquo;<strong>water tablets</strong>&rdquo; (<em>diuretics</em>), <strong>certain types of painkillers</strong> (such as ibuprofen and other similar anti-inflammatories and medicines purchased without a doctor&rsquo;s prescription) and medicines that contain<strong> lithium</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Taking Tecfidera with certain types of vaccines (<em>live vaccines</em>) may cause you to get an infection and should, therefore, be avoided. Your doctor will advise whether other types of vaccines (non-live vaccines) should be given.</p><p>&nbsp;</p><p><strong>Tecfidera with alcohol</strong></p><p>&nbsp;</p><p>Consumption of more than a small quantity (more than 50 ml) of strong alcoholic drinks (more than 30% alcohol by volume, e.g. spirits) should be avoided within an hour of taking Tecfidera, as alcohol can interact with this medicine. This could cause inflammation of the stomach (<em>gastritis</em>), especially in people already prone to gastritis.</p><p><strong>&nbsp;</strong></p><p><strong>Pregnancy and breast-feeding</strong></p><p>&nbsp;</p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p>&nbsp;</p><p><u>Pregnancy</u></p><p>&nbsp;</p><p>Do not use Tecfidera if you are pregnant unless you have discussed this with your doctor.</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p><strong>&nbsp;</strong></p><p>It is not known whether the active substance of Tecfidera passes into breast milk. Tecfidera should not be used during breast-feeding. Your doctor will help you decide whether you should stop breast-feeding, or stop using Tecfidera. This involves balancing the benefit of breast-feeding for your child, and the benefit of therapy for you.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>&nbsp;</p><p>The effect of Tecfidera on the ability to drive or use machines is not known. Tecfidera is not expected to affect your ability to drive and use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&nbsp;Always take this medicine exactly as your doctor has told you. Check with your doctor if you are not sure.</p><p>&nbsp;</p><p><strong>Starting dose</strong></p><p><strong>&nbsp;</strong></p><p><strong>120&nbsp;mg twice a day.</strong></p><p>Take this starting dose for the first 7&nbsp;days, then take the regular dose.</p><p>&nbsp;</p><p><strong>Regular dose</strong></p><p><strong>&nbsp;</strong></p><p><strong>240&nbsp;mg twice a day.</strong></p><p>&nbsp;</p><p>Tecfidera is for oral use</p><p>&nbsp;</p><p><strong>Swallow each capsule whole</strong>, with some water. Do not divide, crush, dissolve, suck or chew the capsule as this may increase some side effects.</p><p>&nbsp;</p><p><strong>Take Tecfidera with food</strong> &ndash; it may help to reduce some of the very common side effects (listed in section&nbsp;4).</p><p><strong>&nbsp;</strong></p><p><strong>If you take more Tecfidera than you should</strong></p><p><strong>&nbsp;</strong></p><p>If you have taken too many capsules, <strong>talk to your doctor straight away</strong>. You may experience side effects similar to those described below in section 4.</p><p><strong>If you forget to take Tecfidera</strong></p><p><strong>&nbsp;</strong></p><p>If you forget or miss a dose, <strong>do not take a double dose</strong>.</p><p>&nbsp;</p><p>You may take the missed dose if you leave at least 4 hours between the doses. Otherwise wait until your next planned dose.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&nbsp;</p><p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p><strong>Serious effects</strong></p><p>&nbsp;</p><p>Tecfidera may lower lymphocyte counts (a type of white blood cell). Having a low white blood cell count can increase your risk of infection, including the risk of a rare brain infection called progressive multifocal leukoencephalopathy (PML). PML may lead to severe disability or death. PML has occurred after 1 to 5 years of treatment and so your physician should continue to monitor your white blood cells throughout your treatment, and you should remain observant of any potential symptoms of PML as described below. The risk of PML may be higher if you have previously taken a medicine impairing the functionality of your body&rsquo;s immune system.</p><p>&nbsp;</p><p>The symptoms of PML may be similar to an MS relapse. Symptoms may include new or worsening weakness on one side of the body; clumsiness; changes in vision, thinking, or memory; or confusion or personality changes, or speech and communication difficulties lasting for more than several days. Therefore, if you believe your MS is getting worse or if you notice any new symptoms while you are on Tecfidera treatment, it is very important that you speak to your doctor as soon as possible. Also speak with your partner or caregivers and inform them about your treatment. Symptoms might arise that you might not become aware of by yourself.</p><p>&nbsp;</p><p>-&nbsp; &nbsp; C<strong>all your doctor straight away if you experience any of these symptoms</strong></p><p>&nbsp;</p><p><strong>Severe Allergic reactions</strong></p><p>&nbsp;</p><p>The frequency of severe allergic reactions cannot be estimated from the available data (not known).</p><p>&nbsp;</p><p>Reddening of the face or body (<em>flushing</em>) is a very common side effect. However, should flushing be accompanied by a red rash or hives <strong>and</strong> you get any of these symptoms:</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling of the face, lips, mouth or tongue <em>(angioedema)</em></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; wheezing, difficulty breathing or shortness of breath <em>(dyspnoea, hypoxia)</em></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dizziness or loss of consciousness <em>(hypotension)</em></p><p>&nbsp;</p><p>then this may represent a severe allergic reaction <em>(anaphylaxis)</em></p><p>&nbsp;</p><p>-&nbsp; &nbsp; &nbsp;&nbsp;<strong>Stop taking Tecfidera and call a doctor straight away</strong>&nbsp;</p><p>&nbsp;</p><p><strong>Very common side effects </strong></p><p>&nbsp;</p><p>These may affect <em>more than 1 in 10 people:</em></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reddening of the face or body feeling warm, hot, burning or itchy<em> (flushing)</em></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; loose stools <em>(diarrhoea)</em></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling sick <em>(nausea)</em></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stomach pain or stomach cramps</p><p>&nbsp;</p><p>-&nbsp; &nbsp; &nbsp;&nbsp;<strong>Taking your medicine with food </strong>can help to reduce the side effects above</p><p><strong>&nbsp;</strong></p><p>Substances called ketones, which are naturally produced in the body, very commonly show up in urine tests while taking Tecfidera.</p><p><strong>&nbsp;</strong></p><p><strong>Talk to your doctor</strong> about how to manage these side effects. Your doctor may reduce your dose. Do not reduce your dose unless your doctor tells you to.</p><p>&nbsp;</p><p><strong>Common side effects</strong></p><p><strong>&nbsp;</strong></p><p>These may affect<em> up to 1 in 10 people:</em></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the lining of the intestines (<em>gastroenteritis</em>)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; being sick <em>(vomiting)</em></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; indigestion (<em>dyspepsia</em>)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the lining of the stomach (<em>gastritis</em>)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; gastrointestinal disorder</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; burning sensation</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hot flush, feeling hot</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; itchy skin (<em>pruritus</em>)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rash</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pink or red blotches on the skin (<em>erythema</em>)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hair loss (<em>alopecia</em>)</p><p><strong>&nbsp;</strong></p><p><u>Side effects which may show up in your blood or urine tests</u></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low levels of white blood cells (<em>lymphopenia, leucopenia</em>) in the blood. Reduced white blood cells could mean your body is less able to fight an infection. If you have a serious infection (such as pneumonia), talk to your doctor immediately</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; proteins (<em>albumin</em>) in urine</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increase in levels of liver enzymes (<em>ALT, AST</em>) in the blood</p><p>&nbsp;</p><p><strong>Uncommon side effects</strong></p><p><strong>&nbsp;</strong></p><p>These may affect <em>up to 1 in 100 people:</em></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; allergic reactions (<em>hypersensitivity</em>)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reduction in blood platelets</p><p>&nbsp;</p><p><strong>Not known</strong> (frequency cannot be estimated from the available data)</p><p><strong>&nbsp;</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; liver inflammation and increase in levels of liver enzymes (<em>ALT or AST in combination with bilirubin</em>)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; herpes zoster (shingles) with symptoms such as blisters, burning, itching or pain of the skin, typically on one side of the upper body or the face, and other symptoms, like fever and weakness in the early stages of infection, followed by numbness, itching or red patches with severe pain</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; runny nose (<em>rhinorrhoea</em>)</p><p><strong>&nbsp;</strong></p><p><strong>Children (13&nbsp;years of age and above) and adolescents</strong></p><p>The side effects listed above also apply to children and adolescents.</p><p>Some side effects were reported more frequently in children and adolescents than in adults, e.g, headache, stomach pain or stomach cramps, being sick <em>(vomiting)</em>, throat pain, cough, and painful menstrual periods.</p><p><strong>&nbsp;</strong></p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system. By reporting side effects you can help provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&nbsp;Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the blister and the carton after &ldquo;EXP&rdquo;.</p><p>The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>Do not store above 30&ordm;C.</p><p>Keep the blisters in the outer carton in order to protect from light.</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to dispose of medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>The active substance</strong> is dimethyl fumarate.</p><p>Tecfidera 120&nbsp;mg: Each capsule contains 120&nbsp;mg of dimethyl fumarate.</p><p>Tecfidera 240&nbsp;mg: Each capsule contains 240&nbsp;mg of dimethyl fumarate.</p><p><strong>&nbsp;</strong></p><p><strong>The other ingredients</strong> are microcrystalline cellulose, croscarmellose sodium, talc, silica colloidal anhydrous, magnesium stearate, triethyl citrate, methacrylic acid &ndash; methyl methacrylate copolymer (1:1), methacrylic acid &ndash; ethyl acrylate copolymer (1:1) dispersion 30%, simeticone, sodium laurilsulfate, polysorbate 80, gelatin, titanium dioxide (E171), brilliant blue FCF (E133), yellow iron oxide (E172), shellac, potassium hydroxide and black iron oxide (E172).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Tecfidera 120 mg gastro-resistant hard capsules are green and white and printed with ‘BG-12 120 mg’ and are available in packs containing 14 capsules.

Tecfidera 240 mg gastro-resistant hard capsules are green and printed with ‘BG-12 240 mg’ and are available in packs containing 56 capsules. 
  
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>&nbsp;</strong><strong>Marketing Authorisation Holder and Final batch releaser</strong></p><p>&nbsp;</p><p>Biogen Netherlands B.V.</p><p>Prins Mauritslaan 13</p><p>1171 LP Badhoevedorp</p><p>The Netherlands</p><p>&nbsp;</p><p><strong>Dosage form manufacturer</strong></p><p>Vifor SA</p><p>Route de Moncor 10</p><p>1752 Villars-sur-Gl&acirc;ne</p><p>Switzerland</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                 06/2022
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>ما</strong><strong> </strong><strong>هو</strong><strong> </strong><strong>تيكفيدرا</strong></p><p dir="RTL">تيكفيدرا هو دواء يحتوي على المادة الفعالة <strong>ديميثيل</strong><strong> </strong><strong>فومارات</strong><strong>.</strong></p><p dir="RTL"><strong>ما</strong><strong> </strong><strong>هي</strong><strong> </strong><strong>دواعي</strong><strong> </strong><strong>استعمال</strong><strong> </strong><strong>تيكفيدرا</strong></p><p dir="RTL"><strong>تيكفيدرا</strong><strong> </strong><strong>يُستخدم</strong><strong> </strong><strong>لعلاج</strong><strong> </strong><strong>التصلّب</strong><strong> </strong><strong>المتعدّد</strong><strong> </strong><strong>الناكس</strong><strong> </strong><strong>المتراجع لدى</strong><strong> </strong><strong>المرضى الذين تبلغ أعمارهم 13 سنة فما فوق</strong><strong> </strong></p><p dir="RTL">التصلب المتعدد هو حالة طويلة الأجل تؤثر على الجهاز العصبي المركزي، بما في ذلك الدماغ والحبل الشوكي . يتميز التصلب المتعدد الناكس المتراجع بنوبات متكررة )انتكاسات (لأعراض الجهاز العصبي. تختلف الأعراض من مريضٍ لآخر، ولكن عادةً ما تتضمن، صعوبات في المشي،&nbsp; شعور بعدم التوازن وصعوبات في الرؤية(مثلاً عدم وضوح الرؤية أو رؤية مزدوجة(.</p><p dir="RTL">قد تختفي هذه الأعراض عندما تنتهي الانتكاسة، ولكن قد تظل بعض المشاكل.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>كيف</strong><strong> </strong><strong>يعمل تيكفيدرا</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">يبدو أن تيكفيدرا يعمل على إيقاف النظام الدفاعي للجسم عن إتلاف الدماغ والحبل الشوكي لديك. قد يساعد ذلك أيضًا في تأخير تفاقم إصابتك بمرض التصلب المتعدد (MS) في المستقبل.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>&nbsp;</strong><strong>لا تتناول</strong><strong> </strong><strong>تيكفيدرا</strong><strong>:</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>إذا</strong><strong> </strong><strong>كانت</strong><strong> </strong><strong>لديك</strong><strong> </strong><strong>حساسية</strong><strong> </strong><strong>تجاه</strong><strong> </strong><strong>ديميثيل فومارات</strong><strong> </strong>أو أي من المكونات الأخرى. لهذا الدواء (المدرجة في القسم رقم ٦) .</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>إذا كان هناك شك في أنك تعاني من عدوى دماغية نادرة تسمى اعتلال بيضاء الدماغ متعدد البؤر التقدمي (</strong><strong>PML</strong><strong>) أو إذا تم تأكيد الإصابة بمرض اعتلال بيضاء الدماغ متعدد البؤر التقدمي (</strong><strong>PML</strong><strong>)</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>تحذيرات واحتياطات</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">قد يؤثر تيكفيدرا على عدد <strong>خلايا</strong><strong> </strong><strong>الدم البيضاء</strong><strong> </strong>لديك، و<strong>الكلى،</strong><strong> </strong><strong>والكبد</strong><strong>. </strong>قبل أن تبدأ في تناول تيكفيدرا، سيجري لك طبيبك اختبار دم لفحص عدد خلايا الدم البيضاء لديك، وسيقوم بالتحقق ما إذا كانت الكلى والكبد لديك يعملان بشكلٍ سليم. سيقوم طبيبك بعمل هذه الاختبارات دوريًا أثناء العلاج. إذا انخفض عدد خلايا الدم البيضاء أثناء العلاج، قد يأخذ طبيبك في الاعتبار إجراءات تحليلية إضافية أو يقوم بإيقاف العلاج.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>استشر</strong><strong> </strong><strong>طبيبك</strong><strong> </strong><strong>قبل</strong><strong> </strong>تناولك تيكفيدرا إذا كنت تعاني من:</p><p dir="RTL">&bull; مرض حاد في <strong>الكلى</strong></p><p dir="RTL">&bull; مرض حاد في <strong>الكبد</strong></p><p dir="RTL">&bull; مرض في <strong>المعدة</strong><strong> </strong>أو <strong>الأمعاء</strong></p><p dir="RTL">&bull; <strong>عدوى</strong><strong> </strong>خطيرة) مثل الالتهاب الرئوي(</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">قد يحدث الهربس النطاقي (القوباء المنطقية) بالتزامن مع العلاج باستعمال تيكفيدرا. في بعض الحالات ، حدثت مضاعفات خطيرة. <strong>يجب عليك إبلاغ طبيبك</strong> على الفور إذا كنت تشك في أن لديك أي أعراض للقوباء المنطقية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنت تعتقد أن إصابتك بالتصلب العصبي المتعدد MS تزداد سوءًا (مثل الضعف أو التغيرات البصرية) أو إذا لاحظت أي أعراض جديدة، فتحدث إلى طبيبك على الفور لأن هذه قد تكون أعراض عدوى دماغية نادرة تسمى اعتلال بيضاء الدماغ متعدد البؤر التقدمي (PML). اعتلال PML هو حالة خطيرة قد تؤدي إلى إعاقة شديدة أو الوفاة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تم الإبلاغ عن اضطرابات نادرة ولكنها خطيرة في الكلى (متلازمة (فانكوني &nbsp;لدواء يحتوي على ديميثيل فومارات، بالاشتراك مع استرات حمض الفوماريك الأخرى، المستخدمة لعلاج الصدفية (مرض جلدي). إذا لاحظت أنك تعاني من ازدياد في البول، أو أنك أكثر عطشًا، أو تشرب أكثر من المعتاد، أو تبدو عضلاتك أضعف، أو لديك تكسر في العظام، أو فقط تعاني من الأوجاع والآلام، تحدث إلى طبيبك في أقرب وقت ممكن حتى يتسنى المزيد من الوقت للبحث في ذلك.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الأطفال</strong><strong> </strong><strong>والمراهقون</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">التحذيرات والاحتياطات المذكورة أعلاه تنطبق أيضًا على الأطفال. يمكن استخدام تيكفيدرا مع الأطفال والمراهقين الذين تبلغ أعمارهم 13 عامًا فما فوق. لا توجد بيانات متاحة للأطفال دون سن 10 سنوات .</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>تيكفيدرا</strong><strong> </strong><strong>مع</strong><strong> </strong><strong>الأدوية</strong><strong> </strong><strong>الأخرى</strong></p><p dir="RTL"><strong>أخبر</strong><strong> </strong><strong>الطبيب</strong><strong> </strong><strong>أو</strong><strong> </strong><strong>الصيدلي</strong><strong> </strong>إذا كنت تتناول، أو تناولت مؤخرًا، أو قد تتناول أي أدوية، وخصوصًا:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;الأدوية التي تحتوي على <strong>استرات</strong><strong> </strong><strong>حمض</strong><strong> </strong><strong>الفوماريك</strong><strong> </strong>) فومارات (المستخدمة في علاج الصدفية.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>الأدوية</strong><strong> </strong><strong>التي</strong><strong> </strong><strong>تؤثر</strong><strong> </strong><strong>على</strong><strong> </strong><strong>نظام</strong><strong> </strong><strong>المناعة في</strong><strong> </strong><strong>الجسم،</strong><strong> </strong>بما في ذلك الأدوية الأخرى المستخدمة في <strong>علاج</strong><strong> </strong><strong>مرض</strong><strong> </strong><strong>التصلب</strong><strong> </strong><strong>المتعدد،</strong><strong> </strong>مثل فينجوليمود، أو ناتاليزوماب، أو تريفلونومد، اليمتزومب، أوكرلذومب أو كلدربين، أو بعض العلاجات شائعة الإستعمال <strong>للسرطان</strong>) ريتوكسيمب أو ميتوكسانترون).</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>الأدوية</strong><strong> </strong><strong>التي</strong><strong> </strong><strong>تؤثر</strong><strong> </strong><strong>على</strong><strong> </strong><strong>الكلى</strong>، <strong>بما في</strong><strong> </strong><strong>ذلك</strong><strong> </strong>بعض <strong>المضادات</strong><strong> </strong><strong>الحيوية </strong>)المستخدمة في علاج الالتهابات(، و&quot;<strong>أقراص</strong><strong> </strong><strong>الماء</strong>&quot; <em>)</em><em>مُدِرَّات</em><em> </em><em>البول</em><em>(</em><em>، </em><strong>وأنواع</strong><strong> </strong><strong>معينة</strong><strong> </strong><strong>من</strong><strong> </strong><strong>المسكنات</strong><strong> </strong>)مثل الإيبوبروفين وغيره من مضادات الالتهاب، والأدوية التي يتم شراؤها من دون وصفة الطبيب(، والأدوية التي تحتوي على <strong>الليثيوم</strong><strong>.</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تناول تكيفيدرا مع أنواع معينة من التطعيمات <em>(اللقاحات</em><em> </em><em>الحية)</em> قد يسبب لك الإصابة بالتهاب ولهذا ينبغي تجنب ذلك. سوف ينصحك طبيبك فيما إذا كان ينبغي إعطاء أنواع أخرى من اللقاحات )اللقاحات غير الحية(.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>تيكفيدرا والكحول</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">ينبغي تجنب استهلاك أكثر من كمية صغيرة )أكثر من 50 مل( من المشروبات الكحولية القوية )أكثر من 30 % من الكحول، من حيث الحجم، على سبيل المثال، المشروبات الروحية(، خلال ساعة من تناول تيكفيدرا، حيث أن الكحول يمكن أن يتفاعل مع هذا الدواء. قد يسبب هذا التهاب في المعدة )<em>الالتهاب المعدي</em>(، خصوصًا لدى الأشخاص المُعرَّضين للالتهاب المعدي.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الحمل</strong><strong> </strong><strong>والرضاعة الطبيعية</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">إذا كنتِ حاملاً أو ترضعين طفلك طبيعيًا، أو تفكرين في أن تصبحين حاملاً أو تخططين لإنجاب طفل، استشِيري طبيبك أو الصيدلي للحصول على المشورة قبل تناول هذا الدواء.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><u>الحمل</u></p><p dir="RTL">لا تستخدمي تيكفيدرا إذا كنتِ حاملاً، ما لم تكوني قد ناقشتِ ذلك مع طبيبك.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><u>الرضاعة الطبيعية</u></p><p dir="RTL"><u>&nbsp;</u></p><p dir="RTL">من غير المعروف ما إذا كانت المادة الفعالة لتيكفيدرا تنتقل إلى حليب الثدي. لا يجب تناول تيكفيدرا أثناء فترة الرضاعة الطبيعية. سيساعدك طبيبك في تقرير ما إذا كان ينبغي عليكِ إيقاف الرضاعة، أو إيقاف استعمال تيكفيدرا. ينطوي ذلك على تحقيق التوازن بين فائدة الرضاعة الطبيعية لطفلك، وفائدة العلاج لكِ.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>تأثير</strong><strong> </strong><strong>تيكفيدرا</strong><strong> </strong><strong>على</strong><strong> </strong><strong>القيادة واستعمال</strong><strong> </strong><strong>الآلات</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">تأثير تيكفيدرا على القيادة أو استعمال الآلات ليس معروفًا. ليس من المتوقع لتيكفيدرا أن يؤثر على قدرتك على القيادة واستعمال الآلات.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">تناول الدواء دائمًا بالضبط كما أخبرك طبيبك. استشر طبيبك إذا لم تكن متأكدًا.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>جرعة</strong><strong> </strong><strong>البداية</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>120 </strong><strong>ملغ،</strong><strong> </strong><strong>مرتين</strong><strong> </strong><strong>يوميًا</strong><strong>.</strong></p><p dir="RTL">تناول جرعة البداية لأول 7 أيام، ثم تناول الجرعة العادية.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الجرعة</strong><strong> </strong><strong>العادية</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>240</strong><strong> </strong><strong>&nbsp;</strong><strong>ملغ،</strong><strong> </strong><strong>مرتين</strong><strong> </strong><strong>يوميًا</strong><strong>.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">يؤخذ تيكفيدرا عن طريق الفم.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>ابتلع</strong><strong> </strong><strong>كل</strong><strong> </strong><strong>كبسولة</strong><strong> </strong><strong>كاملة،</strong><strong> </strong>مع بعض الماء. لا تقسم، أو تحطم، أو تُذيب، أو تمتص، أو تمضغ الكبسولة، حيث أن ذلك قد يزيد من بعض الأعراض الجانبية.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>تناول</strong><strong> </strong><strong>تيكفيدرا</strong><strong> </strong><strong>مع</strong><strong> </strong><strong>الطعام</strong><strong> </strong>&ndash; قد يساعد على تقليل بعض الأعراض الجانبية &nbsp;الشائعة جدًا (المُدرجة في القسم4 )</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>إذا تناولت تيكفيدرا أكثر مما ينبغي</strong></p><p dir="RTL">إذا تناولت عدداً كبيراً من الكبسولات <strong>استشر</strong><strong> </strong><strong>طبيبك</strong><strong> </strong><strong>على</strong><strong> </strong><strong>الفور</strong>. قد تواجه أعراض جانبية مماثلة للأعراض المذكورة في القسم ٤.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا نسيت</strong><strong> </strong><strong>تناول</strong><strong> </strong><strong>جرعة</strong><strong> </strong><strong>تيكفيدرا</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">إذا نسيت تناول جرعة تيكفيدرا، <strong>لا</strong><strong> </strong><strong>تتناول</strong><strong> </strong><strong>جرعة</strong><strong> </strong><strong>مضاعفة</strong><strong>.</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">يمكنك تناول الجرعة المنسية إذا تناولتها بفارق ٤ ساعات على الأقل بين الجرعات. وإلا انتظر حتى يأتي موعد الجرعة المقررة التالية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كانت لديك المزيد من الأسئلة حول استعمال هذا الدواء، اسأل الطبيب أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;</p><p dir="RTL">مثل جميع الأدوية، قد يسبب هذا الدواء ظهور أعراض جانبية، على الرغم من أنها لا تظهر على جميع الأشخاص.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الأعراض</strong><strong> </strong><strong>الجانبية</strong><strong> </strong><strong>الخطيرة</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">قد يقلل تيكفيدرا من عدد الكريات اللمفاوية &nbsp;)نوع من خلايا الدم البيضاء) . وجود انخفاض في عدد خلايا الدم البيضاء يمكن أن يزيد من خطر العدوى ، بما في ذلك مخاطر التهاب الدماغ النادر المعروف باعتلال المادة البيضاء للدماغ (PML). قد يؤدي اعتلال بيضاء الدماغ متعدد البؤر التقدمي إلى إعاقة شديدة أو الموت. حدث اعتلال PML بعد 1 إلى 5 سنوات من العلاج ولذا يجب على طبيبك الاستمرار في مراقبة خلايا الدم البيضاء طوال فترة العلاج، ويجب أن تظل ملاحظًا لأي أعراض محتملة لـ PML كما هو موضح أدناه. قد يكون خطر الإصابة بــ PML أعلى إذا كنت قد تناولت سابقًا دواء يضعف وظائف جهاز المناعة في الجسم.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">قد تكون<strong> </strong>أعراض PML مشابهة لانتكاس مرض التصلب العصبي المتعدد . (MS) قد تشمل الأعراض حالة جديدة من التفاقم أو الضعف في جانب واحد من الجسم ؛ الحركات الفوضوية؛ تغيرات في الرؤية، التفكير أو الذاكرة ، أو الارتباك أو تغيرات في الشخصية أو صعوبات في الكلام والتواصل تستمر لأكثر من عدة أيام. لذلك، إذا كنت تعتقد أن مرض التصلب العصبي المتعدد لديك يزداد سوءًا أو إذا لاحظت أي أعراض جديدة أثناء تلقيك علاج تيكفيدرا، فمن المهم جدًا أن تتحدث إلى طبيبك في أقرب وقت ممكن. تحدث أيضًا مع شريكك أو مقدمي الرعاية وأبلغهم بعلاجك. قد تظهر أعراض قد لا تدركها بنفسك.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">&szlig; <strong>اتصل</strong><strong> </strong><strong>بطبيبك</strong><strong> </strong><strong>على</strong><strong> </strong><strong>الفور</strong><strong> </strong><strong>إذا</strong><strong> </strong><strong>كنت</strong><strong> </strong><strong>تواجه</strong><strong> </strong><strong>أي</strong><strong> </strong><strong>من</strong><strong> </strong><strong>هذه</strong><strong> </strong><strong>الأعراض</strong><strong>.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ردود الفعل التحسسية الشديدة</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">لا يمكن تقدير مدى تكرار ردود الفعل التحسسية الشديدة من البيانات المتاحة (غير معروفة).</p><p dir="RTL">&nbsp;</p><p dir="RTL">يعتبر احمرار الوجه أو الجسم)<em>الاحمرار</em>(هو عارض جانبي شائع جدًا. ولكن، إذا كان الاحمرار مصحوبًا بطفح جلدي أحمر أو الشرى <strong>و</strong>ظهور أي من هذه الأعراض :</p><p dir="RTL">- تورم الوجه، والشفتين، والفم أو اللسان (<em>وذمة</em><em> </em><em>وعائية</em>)</p><p dir="RTL">- الأزيز، وصعوبة في التنفس أو ضيق التنفس(<em> نقص</em><em> </em><em>الأكسجين</em>(</p><p dir="RTL">- الدوخة أو فقدان الوعي (<em>انخفاض ضغط</em><em> </em><em>الدم</em>(</p><p dir="RTL">&nbsp;</p><p dir="RTL">فإن ذلك قد يمثل رد فعل تحسسي شديد) <em>الحساسية المفرطة</em>(</p><p dir="RTL">&nbsp;</p><p dir="RTL">&szlig; <strong>توقف</strong><strong> </strong><strong>عن</strong><strong> </strong><strong>تناول</strong><strong> </strong><strong>تيكفيدرا</strong><strong> </strong><strong>واتصل بطبيبك</strong><strong> </strong><strong>فورًا</strong><strong>.</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>أعراض</strong><strong> </strong><strong>جانبية</strong><strong> </strong><strong>شائعة</strong><strong> </strong><strong>جدًا</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">قد تؤثر هذه الأعراض على أكثر من 1 من كل 10 أشخاص:</p><p dir="RTL">- احمرار الوجه أو الشعور بدفء الجسم، أو السخونة، أو الحرقة، أو الحكة &nbsp;<em>)</em><em> </em><em>احمرار</em><em>(</em></p><p dir="RTL">- &nbsp;براز رخو <em>)</em><em>إسهال</em><em>(</em></p><p dir="RTL">- الشعور بالإعياء <em>)</em><em>الغثيان</em><em>(</em></p><p dir="RTL">- آلام في المعدة أو تقلصات معدية</p><p dir="RTL">&nbsp;</p><p dir="RTL">&szlig; <strong>تناولك</strong><strong> </strong><strong>لدوائك</strong><strong> </strong><strong>مع</strong><strong> </strong><strong>الطعام</strong><strong> </strong>يمكن أن يساعدك على الحد من الأعراض الجانبية المذكورة أعلاه.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُعد أمرًا شائعًا جدًا ظهور المواد التي تسمى الكيتونات، التي يتم إنتاجها طبيعيًا في الجسم، في اختبارات البول، أثناء فترة تناولك لتيكفيدرا.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>استشر</strong><strong> </strong><strong>طبيبك</strong><strong> </strong>بشأن كيفية التعامل مع هذه الأعراض الجانبية. قد يقلل طبيبك من جرعتك من الدواء. لا تقلل جرعتك ما لم يخبرك طبيبك بذلك.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>أعراض</strong><strong> </strong><strong>جانبية</strong><strong> </strong><strong>شائعة</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">قد تؤثر هذه الأعراض على ما يصل إلى <em>1 </em><em>من</em><em> </em><em>كل</em><em> 10 </em><em>أشخاص</em><em>:</em></p><p dir="RTL">&bull; التهاب بطانة الأمعاء <em>)</em><em>التهاب</em><em> </em><em>المعدة والأمعاء</em><em>(</em></p><p dir="RTL">&bull; الإعياء <em>)</em><em>القيء</em><em>(</em></p><p dir="RTL">&bull; عسر الهضم <em>)</em><em>سوء</em><em> </em><em>الهضم</em><em>(</em></p><p dir="RTL">&bull; التهاب بطانة المعدة <em>)</em><em>التهاب</em><em> </em><em>المعدة</em><em>(</em></p><p dir="RTL">&bull; اضطرابات مَعدِية معوية</p><p dir="RTL">&bull; الإحساس بحرقان</p><p dir="RTL">&bull; احمرار مع سخونة، الشعور بالسخونة</p><p dir="RTL">&bull; حكة الجلد <em>)</em><em>الحكة</em><em>(</em></p><p dir="RTL">&bull; الطفح الجلدي</p><p dir="RTL">&bull; بقع وردية أو حمراء على الجلد <em>)</em><em>الحُمامي</em><em>(</em></p><p dir="RTL">&bull;تساقط الشعر (الثعلبة)</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><u>الآثار</u><u> </u><u>الجانبية</u><u> </u><u>التي</u><u> </u><u>قد</u><u> </u><u>تظهر</u><u> </u><u>في</u><u> </u><u>اختبارات الدم</u><u> </u><u>أو</u><u> </u><u>البول</u><u> </u><u>خاصتك</u></p><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مستويات منخفضة لخلايا الدم البيضاء <em>)</em><em>قلة</em><em> </em><em>الليمفاويات،</em><em> </em><em>نقص</em><em> </em><em>كريات</em><em> </em><em>الدم البيضاء).</em><em> </em>قد يعني نقص كريات الدم</p><p dir="RTL">البيضاء أن جسمك أقل قدرة على محاربة العدوى. إذا أصبت بعدوى خطيرة )مثل الالتهاب الرئوي(، استشر طبيبك على الفور.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; البروتينات <em>)</em><em>الزلال</em><em>( </em>في البول.</p><p dir="RTL"><em>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>زيادة في مستويات أنزيمات الكبد في الدم<em>AST) </em><em>&nbsp;،</em><em>ALT</em><em>)</em></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أعراض جانبية غير شائعة</strong></p><p dir="RTL">قد يؤثر ذلك على ما يصل إلى شخص واحد من كل 100 شخص:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات الحساسية <em>(فرط الحساسية)</em></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض في الصفائح الدموية</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير معروفة</strong> (لا يمكن تقدير مدى تكرار الأعراض من البيانات المتاحة)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الكبد وزيادة مستويات إنزيمات الكبد (ALT أو AST بالاشتراك مع البيليروبين)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الهربس النطاقي (القوباء المنطقية) مع أعراض مثل ظهور بثور أو حرقان أو حكة أو ألم في الجلد، عادة على جانب واحد من الجزء العلوي من الجسم أو الوجه، وأعراض أخرى، مثل الحمى وضعف في المراحل المبكرة من الإصابة، تليها خدر أو حكة أو بقع حمراء مع ألم شديد.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيلان الأنف (الثر الأنفي)</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال (13 سنة وما فوق) والمراهقين</strong></p><p dir="RTL">تنطبق الآثار الجانبية المذكورة أعلاه أيضًا على الأطفال والمراهقين.</p><p dir="RTL">تم الإبلاغ عن بعض الآثار الجانبية بشكل متكرر لدى الأطفال والمراهقين أكثر من البالغين، مثل الصداع وآلام المعدة أو تقلصات المعدة والغثيان (القيء) وآلام الحلق والسعال وألم الدورة الشهرية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>للإبلاغ</strong><strong> </strong><strong>عن</strong><strong> </strong><strong>اية</strong><strong> </strong><strong>أعراض</strong><strong> </strong><strong>جانبية</strong><strong>:</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">إذا ظهرت عليك أي أعراض جانبية، تحدث مع طبيبك أو الصيدلي. وهذا يشمل أي آثار جانبية غير مدرجة في هذه النشرة. يمكنك أيضا الإبلاغ عن الآثار الجانبية مباشرة من خلال نظام الإبلاغ الوطني. من خلال الإبلاغ عن الآثار الجانبية التي يمكن أن تساعد على توفير مزيد من المعلومات حول سلامة هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يُحفظ بعيدًا عن متناول ومرأى الأطفال.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستخدم هذا الدواء بعد انتهاء مدة صلاحيته المذكورة على النفطة والعبوة الكرتونية&rdquo; بعد كلمة .&ldquo;EXP</p><p dir="RTL">&nbsp;&nbsp;يشير تاريخ انتهاء الصلاحية إلى آخر يوم من ذلك الشهر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يحفظ في درجة حرارة لا تتعدّى 30 درجة مئوية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تحفظ النفطة في العبوة الكرتونية لحمايتها من الضوء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تتخلص من أي أدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية.</p><p dir="RTL">اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد تستعملها. ستساعد هذه التدابير على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>ما</strong><strong> </strong><strong>هي</strong><strong> </strong><strong>محتويات</strong><strong> </strong><strong>تيكفيدرا</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>المادة</strong><strong> </strong><strong>الفعالة</strong><strong> </strong>هي ديميثيل فومارات</p><p dir="RTL">تيكفيدرا 120 ملغ: كل كبسولة تحتوي على 120 ملغ من ديميثيل فومارات.</p><p dir="RTL">تيكفيدرا 240 ملغ: كل كبسولة تحتوي على 240 ملغ من ديميثيل فومارات.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>المكونات</strong><strong> </strong><strong>الأخرى</strong><strong> </strong>هي ميكروكرستلاين سليلوز، وكروس كارميلوز الصوديوم، والتلك، والسليكا، وهيدروفوبك كولويدل، وستيرات المغنيسيوم، وثلاثي إيثيل السيترات، وحمض الميثاكريليك &ndash; كوبوليمر ميثيل ميتاكريليت (1:1) ، حمض) ميثاكريليك &ndash; &nbsp;كوبوليمر إيثيل أكريلات&nbsp; (1:1)&nbsp; التشتت 30%،&nbsp; وسيميثيكون، وصوديوم لوريل سولفات، وبولي سوربات 80 ، وجيلاتين وأزرق براق (E133) FCF وأكسيد الحديد، الأصفر (E 172)وشيلاك، وهيدروكسيد البوتاسيوم، وأكسيد الحديد الأسود (E172).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="text-align:right"><strong>&nbsp;</strong></p><p dir="RTL" style="text-align:right"><strong>ما</strong><strong> </strong><strong>هو</strong><strong> </strong><strong>الشكل</strong><strong> </strong><strong>الصيدلاني</strong><strong> </strong><strong>لتيكفيدرا ومحتويات العبوة</strong></p><p dir="RTL" style="text-align:right">&nbsp;</p><p dir="RTL" style="text-align:right">تيكفيدرا 120 ملغ لمقاومة العصارة المعدية، يأتي في كبسولات صلبة خضراء وبيضاء مطبوع عليها &rdquo;BG-12 120 mg&rdquo; &nbsp;ويتوفر في عبوات تحتوي على 14 كبسولة.</p><p dir="RTL" style="text-align:right">&nbsp;</p><p dir="RTL" style="text-align:right">تيكفيدرا 240 ملغ لمقاومة العصارة المعدية، يأتي في كبسولات صلبة خضراء مطبوع عليها&rdquo;BG-12 240 mg&rdquo;</p><p dir="RTL" style="text-align:right">ويتوفر في عبوات تحتوي على 56 كبسولة</p><p dir="RTL" style="text-align:right"><strong>&nbsp;</strong></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="ltr"><strong>&nbsp;</strong></p><p dir="RTL"><strong>مالك</strong><strong> </strong><strong>رخصة</strong><strong> </strong><strong>التسويق والمصنع </strong><strong>المسؤول</strong><strong> </strong><strong>عن</strong><strong> </strong><strong>تحرير</strong><strong> </strong><strong>الصنف</strong></p><p>Biogen Netherlands B.V.</p><p>Prins Mauritslaan 13</p><p>1171 LP Badhoevedorp</p><p>The Netherlands/هولندا</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>مصنع</strong><strong> </strong><strong>الشكل</strong><strong> </strong><strong>الصيدلاني</strong></p><p dir="RTL">Vifor SA</p><p dir="RTL">Route de Moncor 10 1752 Villars-sur-Gl&acirc;ne</p><p dir="RTL">Switzerland</p><p dir="RTL">سويسرا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
             06/2022
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                 Tecfidera 120 mg gastro-resistant hard capsules
Tecfidera 240 mg gastro-resistant hard capsules


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                 Tecfidera 120 mg gastro-resistant hard capsules

Each gastro-resistant hard capsule contains 120 mg dimethyl fumarate

Tecfidera 240 mg gastro-resistant hard capsules

Each gastro-resistant hard capsule contains 240 mg dimethyl fumarate

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                 Gastro-resistant hard capsule

Tecfidera 120 mg gastro-resistant hard capsules

Green and white gastro-resistant hard capsules, size 0, printed with ‘BG-12 120 mg’ containing microtablets.

Tecfidera 240 mg gastro-resistant hard capsules

Green gastro-resistant hard capsules, size 0, printed with ‘BG-12 240 mg’ containing microtablets.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Tecfidera is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (RRMS).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;Treatment should be initiated under supervision of a physician experienced in the treatment of multiple sclerosis.</p><p>&nbsp;</p><p><u>Posology</u></p><p>&nbsp;</p><p>The starting dose is 120&nbsp;mg twice a day. After 7&nbsp;days, the dose should be increased to the recommended maintenance dose of 240 mg twice a day (see section 4.4).</p><p>&nbsp;</p><p>If a patient misses a dose, a double dose should not be taken. The patient may take the missed dose only if they leave 4 hours between doses. Otherwise the patient should wait until the next scheduled dose.</p><p>&nbsp;</p><p>Temporary dose reduction to 120&nbsp;mg twice a day may reduce the occurrence of flushing and gastrointestinal adverse reactions. Within 1&nbsp;month, the recommended maintenance dose of 240&nbsp;mg twice a day should be resumed.</p><p>&nbsp;</p><p>Tecfidera should be taken with food (see section&nbsp;5.2). For those patients who may experience flushing or gastrointestinal adverse reactions, taking Tecfidera with food may improve tolerability (see sections&nbsp;4.4,&nbsp;4.5 and&nbsp;4.8).</p><p>&nbsp;</p><p><em>Special populations</em></p><p>&nbsp;</p><p><em>Elderly</em></p><p>Clinical studies of Tecfidera had limited exposure to patients aged 55&nbsp;years and above, and did not include sufficient numbers of patients aged 65&nbsp;and over to determine whether they respond differently than younger patients (see section&nbsp;5.2). Based on the mode of action of the active substance there are no theoretical reasons for any requirement for dose adjustments in the elderly.</p><p>&nbsp;</p><p><em>Renal and hepatic impairment</em></p><p>Tecfidera has not been studied in patients with renal or hepatic impairment. Based on clinical pharmacology studies, no dose adjustments are needed (see section&nbsp;5.2). Caution should be used when treating patients with severe renal or severe hepatic impairment (see section&nbsp;4.4).</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>The posology is the same in adults and in paediatric patients aged 13 years and older.</p><p>Currently available data are described in sections 4.4, 4.8, 5.1, and 5.2.</p><p>&nbsp;</p><p>There are limited data available in children between 10 and 12 years old.</p><p>The safety and efficacy of Tecfidera in children aged less than 10 years have not yet been established.</p><p>&nbsp;</p><p><u>Method of administration </u></p><p>&nbsp;</p><p>For oral use.</p><p>&nbsp;</p><p>The capsule should be swallowed whole. The capsule or its contents should not be crushed, divided, dissolved, sucked or chewed as the enteric-coating of the microtablets prevents irritant effects on the gut.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                 Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Suspected or confirmed Progressive Multifocal Leukoencephalopathy (PML)

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Blood/laboratory tests</u></p><p>Changes in renal laboratory tests have been seen in clinical trials in patients treated with dimethyl fumarate (see section&nbsp;4.8). The clinical implications of these changes are unknown. Assessment of renal function (e.g. creatinine, blood urea nitrogen and urinalysis) is recommended prior to treatment initiation, after 3&nbsp;and 6&nbsp;months of treatment, every 6&nbsp;to 12&nbsp;months thereafter and as clinically indicated.</p><p>&nbsp;</p><p>Drug-induced liver injury, including liver enzyme increase (&ge; 3 upper limit of normal (ULN)) and elevation of total bilirubin levels (&ge; 2 ULN) can result from treatment with dimethyl fumarate. The time to onset can be directly, several weeks or longer. Resolution of the adverse reactions has been observed after treatment was discontinued. Assessment of serum aminotransferases (e.g. alanine aminotransferase (ALT), aspartate aminotransferase (AST)) and total bilirubin levels are recommended prior to treatment initiation and during treatment as clinically indicated.</p><p>&nbsp;</p><p>Patients treated with Tecfidera may develop lymphopenia (see section&nbsp;4.8). Prior to initiating treatment with Tecfidera, a current complete blood count, including lymphocytes, must be performed.</p><p>&nbsp;</p><p>If lymphocyte count is found to be below the normal range, thorough assessment of possible causes should be completed prior to initiation of treatment with Tecfidera. Dimethyl fumarate has not been studied in patients with pre-existing low lymphocyte counts and caution should be exercised when treating these patients. Tecfidera should not be initiated in patients with severe lymphopenia (lymphocyte counts &lt; 0.5&nbsp;x&nbsp;10<sup>9</sup>/L).</p><p>&nbsp;</p><p>After starting therapy, complete blood counts, including lymphocytes, must be performed every 3 months.</p><p>&nbsp;</p><p>Enhanced vigilance due to an increased risk for Progressive Multifocal Leukoencephalopathy (PML) is recommended in patients with lymphopenia as follows:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tecfidera should be discontinued in patients with prolonged severe lymphopenia (lymphocyte counts &lt; 0.5&nbsp;x&nbsp;10<sup>9</sup>/L) persisting for more than 6&nbsp;months.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In patients with sustained moderate reductions of absolute lymphocyte counts &ge;0.5&nbsp;x&nbsp;10<sup>9</sup>/L to &lt;&nbsp;0.8&nbsp;x&nbsp;10<sup>9</sup>/L for more than 6 months, the benefit/risk of Tecfidera treatment should be re-assessed.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In patients with lymphocyte counts below lower limit of normal (LLN) as defined by local laboratory reference range, regular monitoring of absolute lymphocyte counts is recommended. Additional factors that might further augment the individual PML risk should be considered (see subsection on PML below).</p><p>&nbsp;</p><p>Lymphocyte counts should be followed until recovery (see section 5.1). Upon recovery and in the absence of alternative treatment options, decisions about whether or not to restart Tecfidera after treatment discontinuation should be based on clinical judgement.</p><p>&nbsp;</p><p><u>Magnetic Resonance imaging (MRI)</u></p><p>Before initiating treatment with Tecfidera, a baseline MRI should be available (usually within 3 months) as a reference. The need for further MRI scanning should be considered in accordance with national and local recommendations. MRI imaging may be considered as part of increased vigilance in patients considered at increased risk of PML. In case of clinical suspicion of PML, MRI should be performed immediately for diagnostic purposes.</p><p><u>&nbsp;</u></p><p><u>Progressive Multifocal Leukoencephalopathy (PML)</u></p><p>PML has been reported in patients treated with Tecfidera (see section 4.8). PML is an opportunistic infection caused by John-Cunningham virus (JCV), which may be fatal or result in severe disability.</p><p>&nbsp;</p><p>PML cases have occurred with dimethyl fumarate and other medicinal products containing fumarates in the setting of lymphopenia (lymphocyte counts below LLN). Prolonged moderate to severe lymphopenia appears to increase the risk of PML with Tecfidera, however, risk cannot be excluded in patients with mild lymphopenia.</p><p>&nbsp;</p><p>Additional factors that might contribute to an increased risk for PML in the setting of lymphopenia are:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; duration of Tecfidera therapy. Cases of PML have occurred after approximately 1&nbsp;to&nbsp;5&nbsp;years of treatment, although the exact relationship with duration of treatment is unknown<em>.</em></p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; profound decreases in CD4+ and especially in CD8+ T&nbsp;cell counts, which are important for immunological defence (see section 4.8), and</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; prior immunosuppressive or immunomodulatory therapy (see below).</p><p>&nbsp;</p><p>Physicians should evaluate their patients to determine if the symptoms are indicative of neurological dysfunction and, if so, whether these symptoms are typical of MS or possibly suggestive of PML.</p><p>&nbsp;</p><p>At the first sign or symptom suggestive of PML, Tecfidera should be withheld and appropriate diagnostic evaluations, including determination of JCV DNA in cerebrospinal fluid (CSF) by quantitative polymerase chain reaction (PCR) methodology, need to be performed. The symptoms of PML may be similar to an MS relapse. Typical symptoms associated with PML are diverse, progress over days to weeks, and include progressive weakness on one side of the body or clumsiness of limbs, disturbance of vision, and changes in thinking, memory, and orientation leading to confusion and personality changes. Physicians should be particularly alert to symptoms suggestive of PML that the patient may not notice. Patients should also be advised to inform their partner or caregivers about their treatment, since they may notice symptoms that the patient is not aware of.</p><p>&nbsp;</p><p>PML can only occur in the presence of a JCV infection. It should be considered that the influence of lymphopenia on the accuracy of serum anti-JCV antibody testing has not been studied in dimethyl fumarate treated patients. It should also be noted that a negative anti-JCV antibody test (in the presence of normal lymphocyte counts) does not preclude the possibility of subsequent JCV infection.</p><p>&nbsp;</p><p>If a patient develops PML, Tecfidera must be permanently discontinued.</p><p>&nbsp;</p><p><u>Prior treatment with immunosuppressive or immunomodulating therapies</u></p><p>No studies have been performed evaluating the efficacy and safety of Tecfidera when switching patients from other disease modifying therapies to Tecfidera. The contribution of prior immunosuppressive therapy to the development of PML in dimethyl fumarate treated patients is possible.</p><p>&nbsp;</p><p>PML cases have occurred in patients who had previously been treated with natalizumab, for which PML is an established risk. Physicians should be aware that cases of PML occurring following recent discontinuation of natalizumab may not have lymphopenia.</p><p>&nbsp;</p><p>In addition, a majority of confirmed PML cases with Tecfidera occurred in patients with prior immunomodulatory treatment.</p><p>&nbsp;</p><p>When switching patients from another disease modifying therapy to Tecfidera, the half-life and mode of action of the other therapy should be considered in order to avoid an additive immune effect while at the same time, reducing the risk of reactivation of MS. A complete blood count is recommended prior to initiating Tecfidera and regularly during treatment (see Blood/laboratory tests above).</p><p>&nbsp;</p><p><u>Severe renal and hepatic impairment</u></p><p><u>&nbsp;</u></p><p>Tecfidera has not been studied in patients with severe renal or severe hepatic impairment and caution should, therefore, be used in these patients (see section&nbsp;4.2).</p><p>&nbsp;</p><p><u>Severe active gastrointestinal disease</u></p><p><u>&nbsp;</u></p><p>Tecfidera has not been studied in patients with severe active gastrointestinal disease and caution should, therefore, be used in these patients.</p><p>&nbsp;</p><p><u>Flushing</u></p><p><u>&nbsp;</u></p><p>In clinical trials, 34% of Tecfidera treated patients experienced flushing. In the majority of patients who experienced flushing, it was mild or moderate in severity. Data from healthy volunteer studies suggest that dimethyl fumarate-associated flushing is likely to be prostaglandin mediated. A short course of treatment with 75 mg non-enteric coated acetylsalicylic acid may be beneficial in patients affected by intolerable flushing (see section 4.5). In two healthy volunteer studies, the occurrence and severity of flushing over the dosing period was reduced.</p><p>&nbsp;</p><p>In clinical trials, 3 patients out of a total of 2,560&nbsp;patients treated with dimethyl fumarate experienced serious flushing symptoms that were probable hypersensitivity or anaphylactoid reactions. These events were not life-threatening, but led to hospitalisation. Prescribers and patients should be alert to this possibility in the event of severe flushing reactions (see sections&nbsp;4.2,&nbsp;4.5 and&nbsp;4.8).</p><p><u>&nbsp;</u></p><p><u>Anaphylactic reactions</u></p><p><u>&nbsp;</u></p><p>Cases of anaphylaxis/anaphylactoid reaction have been reported following Tecfidera administration in the post-marketing setting. Symptoms may include dyspnoea, hypoxia, hypotension, angioedema, rash or urticaria. The mechanism of dimethyl fumarate induced anaphylaxis is unknown. Reactions generally occur after the first dose, but may also occur at any time during treatment, and may be serious and life threatening. Patients should be instructed to discontinue Tecfidera and seek immediate medical care if they experience signs or symptoms of anaphylaxis. Treatment should not be restarted (see section 4.8).</p><p><u>&nbsp;</u></p><p><u>Infections</u></p><p><u>&nbsp;</u></p><p>In phase III placebo-controlled studies, the incidence of infections (60% vs 58%) and serious infections (2% vs 2%) was similar in patients treated with Tecfidera or placebo, respectively. However, due to Tecfidera immunomodulatory properties (see section 5.1), if a patient develops a serious infection, suspending treatment with Tecfidera should be considered and the benefits and risks should be reassessed prior to re-initiation of therapy. Patients receiving Tecfidera should be instructed to report symptoms of infections to a physician. Patients with serious infections should not start treatment with Tecfidera until the infection(s) is resolved.</p><p>&nbsp;</p><p>There was no increased incidence of serious infections observed in patients with lymphocyte counts &lt; 0.8 x 10<sup>9</sup>/L or &lt; 0.5 x 10<sup>9</sup>/L (see section 4.8). &nbsp;If therapy is continued in the presence of moderate to severe prolonged lymphopenia, the risk of an opportunistic infection, including PML, cannot be ruled out (see section 4.4 subsection PML).</p><p>&nbsp;</p><p><u>Herpes zoster infections</u></p><p>&nbsp;</p><p>Cases of herpes zoster have occurred with Tecfidera. The majority of cases were non-serious, however, serious cases, including disseminated herpes zoster, herpes zoster ophthalmicus, herpes zoster oticus, herpes zoster infection neurological<em>,</em> herpes zoster meningoencephalitis and herpes zoster meningomyelitis have been reported. These events may occur at any time during treatment. Monitor patients taking Tecfidera for signs and symptoms of herpes zoster especially when concurrent lymphocytopenia is reported. If herpes zoster occurs, appropriate treatment for herpes zoster should be administered. Consider withholding Tecfidera treatment in patients with serious infections until the infection has resolved (see section 4.8).</p><p>&nbsp;</p><p><u>Treatment initiation</u></p><p>&nbsp;</p><p>Tecfidera treatment should be started gradually to reduce the occurrence of flushing and gastrointestinal adverse reactions (see section 4.2).</p><p><u>&nbsp;</u></p><p><u>Fanconi syndrome</u></p><p>&nbsp;</p><p>Cases of Fanconi syndrome have been reported for a medicinal product containing dimethyl fumarate in combination with other fumaric acid esters. Early diagnosis of Fanconi syndrome and discontinuation of dimethyl fumarate treatment are important to prevent the onset of renal impairment and osteomalacia, as the syndrome is usually reversible. The most important signs are proteinuria, glucosuria (with normal blood sugar levels), hyperaminoaciduria and phosphaturia (possibly concurrent with hypophosphatemia). Progression might involve symptoms such as polyuria, polydipsia and proximal muscle weakness. In rare cases hypophosphataemic osteomalacia with non-localised bone pain, elevated alkaline phosphatase in serum and stress fractures may occur. Importantly, Fanconi syndrome can occur without elevated creatinine levels or low glomerular filtration rate. In case of unclear symptoms Fanconi syndrome should be considered and appropriate examinations should be performed.</p><p><u>Paediatric population</u></p><p><u>&nbsp;</u></p><p>The safety profile is qualitatively similar in paediatric patients compared to adults and therefore the warnings and precautions also apply to the paediatric patients. For quantitative differences in the safety profile see section 4.8.</p><p>&nbsp;</p><p>The long-term safety of Tecfidera in paediatric population has not yet been established.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;Tecfidera has not been studied in combination with anti-neoplastic or immunosuppressive therapies and caution should, therefore, be used during concomitant administration. In multiple sclerosis clinical studies, the concomitant treatment of relapses with a short course of intravenous corticosteroids was not associated with a clinically relevant increase of infection.</p><p>&nbsp;</p><p>Concomitant administration of non-live vaccines according to national vaccination schedules may be considered during Tecfidera therapy. In a clinical study involving a total of 71 patients with relapsing remitting multiple sclerosis, patients on Tecfidera 240 mg twice daily for at least 6 months (n=38) or non-pegylated interferon for at least 3 months (n=33), mounted a comparable immune response (defined as &ge;2-fold increase from pre- to post-vaccination titer) to tetanus toxoid (recall antigen) and a conjugated meningococcal C polysaccharide vaccine (neoantigen), while the immune response to different serotypes of an unconjugated 23-valent pneumococcal polysaccharide vaccine (T-cell independent antigen) varied in both treatment groups. A positive immune response defined as a &ge;4‑fold increase in antibody titer to the three vaccines, was achieved by fewer subjects in both treatment groups. Small numerical differences in the response to tetanus toxoid and pneumococcal serotype 3 polysaccharide were noted in favour of non-pegylated interferon.</p><p>&nbsp;</p><p>No clinical data are available on the efficacy and safety of live attenuated vaccines in patients taking Tecfidera. Live vaccines might carry an increased risk of clinical infection and should not be given to patients treated with Tecfidera unless, in exceptional cases, this potential risk is considered to be outweighed by the risk to the individual of not vaccinating.</p><p>&nbsp;</p><p>During treatment with Tecfidera, simultaneous use of other fumaric acid derivatives (topical or systemic) should be avoided.</p><p>&nbsp;</p><p>In humans, dimethyl fumarate is extensively metabolised by esterases before it reaches the systemic circulation and further metabolism occurs through the tricarboxylic acid cycle, with no involvement of the cytochrome P450 (CYP) system. Potential drug interaction risks were not identified from <em>in vitro</em> CYP-inhibition and induction studies, a p-glycoprotein study, or studies of the protein binding of dimethyl fumarate and monomethyl fumarate (a primary metabolite of dimethyl fumarate).</p><p>&nbsp;</p><p>Commonly used medicinal products in patients with multiple sclerosis, intramuscular interferon beta‑1a and glatiramer acetate, were clinically tested for potential interactions with dimethyl fumarate and did not alter the pharmacokinetic profile of dimethyl fumarate.</p><p>&nbsp;</p><p>Evidence from healthy volunteer studies suggests that Tecfidera-associated flushing is likely to be prostaglandin mediated. In two healthy volunteer studies, the administration of 325&nbsp;mg (or equivalent) non‑enteric coated acetylsalicylic acid, 30&nbsp;minutes prior to Tecfidera, dosing over 4&nbsp;days and over 4 weeks, respectively, did not alter the pharmacokinetic profile of Tecfidera. Potential risks associated with acetylsalicylic acid therapy should be considered prior to co-administration with Tecfidera in patients with Relapsing Remitting MS. Long term (&gt;&nbsp;4&nbsp;weeks) continuous use of acetylsalicylic acid has not been studied (see sections&nbsp;4.4 and&nbsp;4.8).</p><p>&nbsp;</p><p>Concurrent therapy with nephrotoxic medicinal products (such as aminoglycosides, diuretics, non-steroidal anti-inflammatory drugs or lithium) may increase the potential of renal adverse reactions (e.g. proteinuria see section 4.8) in patients taking Tecfidera (see section&nbsp;4.4 Blood/laboratory tests).</p><p><u>&nbsp;</u></p><p>Consumption of moderate amounts of alcohol did not alter exposure to dimethyl fumarate and was not associated with an increase in adverse reactions. Consumption of large quantities of strong alcoholic drinks (more than 30% alcohol by volume) should be avoided within an hour of taking Tecfidera, as alcohol may lead to increased frequency of gastrointestinal adverse reactions.</p><p>&nbsp;</p><p><em>In vitro</em> CYP induction studies did not demonstrate an interaction between Tecfidera and oral contraceptives. In an <em>in vivo</em> study, co-administration of Tecfidera with a combined oral contraceptive (norgestimate and ethinyl estradiol) did not elicit any relevant change in oral contraceptive exposure. No interaction studies have been performed with oral contraceptives containing other progestogens, however an effect of Tecfidera on their exposure is not expected.</p><p><u>&nbsp;</u></p><p><u>Paediatric population</u></p><p>&nbsp;</p><p>Interaction studies have only been performed in adults.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>&nbsp;</p><p>There are no or limited amount of data from the use of dimethyl fumarate in pregnant women. Animal studies have shown reproductive toxicity (see section&nbsp;5.3). Tecfidera is not recommended during pregnancy and in women of childbearing potential not using appropriate contraception (see section&nbsp;4.5). Tecfidera should be used during pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the foetus.</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p>&nbsp;</p><p>It is unknown whether dimethyl fumarate or its metabolites are excreted in human milk. A risk to the newborns/infants cannot be excluded. A decision must be made whether to discontinue breast-feeding or to discontinue Tecfidera therapy. The benefit of breast-feeding for the child and the benefit of therapy for the woman should be taken into account.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>&nbsp;</p><p>There are no data on the effects of dimethyl fumarate on human fertility. Data from preclinical studies do not suggest that dimethyl fumarate would be associated with an increased risk of reduced fertility (see section&nbsp;5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;Tecfidera has no or negligible influence on the ability to drive and use machines. No studies on the ability to drive and use machines have been conducted but no effects potentially influencing this ability were found to be related to dimethyl fumarate in clinical studies.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>&nbsp;</p><p>The most common adverse reactions (incidence &ge; 10%) for patients treated with dimethyl fumarate were flushing and gastrointestinal events (i.e. diarrhoea, nausea, abdominal pain, abdominal pain upper). Flushing and gastrointestinal events tend to begin early in the course of treatment (primarily during the first month) and in patients who experience flushing and gastrointestinal events, these events may continue to occur intermittently throughout treatment with Tecfidera. The most commonly reported adverse reactions leading to discontinuation (incidence &gt;1%) in patients treated with Tecfidera were flushing (3%) and gastrointestinal events (4%).</p><p>&nbsp;</p><p>In placebo-controlled and uncontrolled clinical studies, a total of 2,513&nbsp;patients have received Tecfidera for periods of up to 12&nbsp;years with an overall exposure equivalent to 11,318&nbsp;person-years. A total of 1,169&nbsp;patients have received at least 5 years of treatment with Tecfidera and 426 patients have received at least 10 years of treatment with Tecfidera. The experience in uncontrolled clinical trials is consistent with the experience in the placebo-controlled clinical trials.</p><p>&nbsp;</p><p><u>Tabulated summary of adverse reactions</u></p><p>&nbsp;</p><p>Adverse reactions, arising from clinical studies, post-authorisation safety studies and spontaneous reports, are presented in the table below.</p><p>&nbsp;</p><p>The adverse reactions are presented as MedDRA preferred terms under the MedDRA System Organ Class. The incidence of the adverse reactions below is expressed according to the following categories:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Very common (&ge;1/10)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Common (&ge;1/100 to &lt;1/10)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Uncommon (&ge;1/1,000 to &lt;1/100)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rare (&ge;1/10, 000 to &lt;1/1,000)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Very rare (&lt;1/10,000)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Not known (frequency cannot be estimated from the available data)</p><p><em>&nbsp;</em></p><table cellspacing="0" cellpadding="0" border="1" style="width:605px"><thead><tr><td><p><strong>MedDRA System Organ Class</strong></p></td><td><p><strong>Adverse reaction</strong></p></td><td><p><strong>Frequency category</strong></p></td></tr></thead><tbody><tr><td rowspan="3" style="vertical-align:top"><p>Infections and infestations</p></td><td><p>Gastroenteritis</p></td><td><p>Common</p></td></tr><tr><td><p>Progressive multifocal leukoencephalopathy (PML)<sup> </sup></p></td><td><p>Not known</p></td></tr><tr><td><p>Herpes zoster</p></td><td><p>Not known</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td><p>Lymphopenia</p></td><td><p>Common</p></td></tr><tr><td><p>Leucopenia</p></td><td><p>Common</p></td></tr><tr><td><p>Thrombocytopenia</p></td><td><p>Uncommon</p></td></tr><tr><td rowspan="6" style="vertical-align:top"><p>Immune system disorders</p></td><td><p>Hypersensitivity</p></td><td><p>Uncommon</p></td></tr><tr><td><p>Anaphylaxis</p></td><td><p>Not known</p></td></tr><tr><td><p>Dyspnoea</p></td><td><p>Not known</p></td></tr><tr><td><p>Hypoxia</p></td><td><p>Not known</p></td></tr><tr><td><p>Hypotension</p></td><td><p>Not known</p></td></tr><tr><td><p>Angioedema</p></td><td><p>Not known</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td><p>Burning sensation</p></td><td><p>Common</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Vascular disorders</p></td><td><p>Flushing</p></td><td><p>Very common</p></td></tr><tr><td><p>Hot flush</p></td><td><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td><p>Rhinorrhoea</p></td><td><p>Not known</p></td></tr><tr><td rowspan="8" style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td><p>Diarrhoea</p></td><td><p>Very common</p></td></tr><tr><td><p>Nausea</p></td><td><p>Very common</p></td></tr><tr><td><p>Abdominal pain upper</p></td><td><p>Very common</p></td></tr><tr><td><p>Abdominal pain</p></td><td><p>Very common</p></td></tr><tr><td><p>Vomiting</p></td><td><p>Common</p></td></tr><tr><td><p>Dyspepsia</p></td><td><p>Common</p></td></tr><tr><td><p>Gastritis</p></td><td><p>Common</p></td></tr><tr><td><p>Gastrointestinal disorder</p></td><td><p>Common</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Hepatobiliary disorders</p></td><td><p>Aspartate aminotransferase increased</p></td><td><p>Common</p></td></tr><tr><td><p>Alanine aminotransferase increased</p></td><td><p>Common</p></td></tr><tr><td><p>Drug-induced liver injury</p></td><td><p>Not known</p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td><p>Pruritus</p></td><td><p>Common</p></td></tr><tr><td><p>Rash</p></td><td><p>Common</p></td></tr><tr><td><p>Erythema</p></td><td><p>Common</p></td></tr><tr><td><p>Alopecia</p></td><td><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Renal and urinary disorders</p></td><td><p>Proteinuria</p></td><td><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td><p>Feeling hot</p></td><td><p>Common</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Investigations</p></td><td><p>Ketones measured in urine</p></td><td><p>Very common</p></td></tr><tr><td><p>Albumin urine present</p></td><td><p>Common</p></td></tr><tr><td><p>White blood cell count decreased</p></td><td><p>Common</p></td></tr></tbody></table><p><strong><em><sup>&nbsp;</sup></em></strong></p><p>&nbsp;</p><p><u>Description of selected adverse reactions</u></p><p>&nbsp;</p><p><em>Flushing </em></p><p><em>&nbsp;</em></p><p>In the placebo-controlled studies, the incidence of flushing (34%&nbsp;versus&nbsp;4%) and hot flush (7%&nbsp;versus&nbsp;2%) was increased in patients treated with Tecfidera compared to placebo, respectively. Flushing is usually described as flushing or hot flush, but can include other events (e.g. warmth, redness, itching, and burning sensation). Flushing events tend to begin early in the course of treatment (primarily during the first month) and in patients who experience flushing, these events may continue to occur intermittently throughout treatment with Tecfidera. In patients with flushing, the majority had flushing events that were mild or moderate in severity. Overall, 3% of patients treated with Tecfidera discontinued due to flushing. The incidence of serious flushing, which may be characterised by generalised erythema, rash and/or pruritus, was seen in less than 1% of patients treated with Tecfidera (see&nbsp;sections&nbsp;4.2,&nbsp;4.4 and&nbsp;4.5).</p><p>&nbsp;</p><p><em>Gastrointestinal</em></p><p>&nbsp;</p><p>The incidence of gastrointestinal events (e.g. diarrhoea [14%&nbsp;versus&nbsp;10%], nausea [12%&nbsp;versus&nbsp;9%], upper abdominal pain [10%&nbsp;versus&nbsp;6%], abdominal pain [9%&nbsp;versus&nbsp;4%], vomiting [8%&nbsp;versus&nbsp;5%] and dyspepsia [5%&nbsp;versus&nbsp;3%]) was increased in patients treated with Tecfidera compared to placebo, respectively. Gastrointestinal events tend to begin early in the course of treatment (primarily during the first month) and in patients who experience gastrointestinal events, these events may continue to occur intermittently throughout treatment with Tecfidera. In the majority of patients who experienced gastrointestinal events, it was mild or moderate in severity. Four per cent (4%) of patients treated with Tecfidera discontinued due to gastrointestinal events. The incidence of serious gastrointestinal events, including gastroenteritis and gastritis, was seen in 1% of patients treated with Tecfidera (see section&nbsp;4.2).</p><p>&nbsp;</p><p><em>Hepatic function </em></p><p><em>&nbsp;</em></p><p>Based on data from placebo-controlled studies, the majority of patients with elevations had hepatic transaminases that were &lt; 3&nbsp;times the upper limit of normal (ULN). The increased incidence of elevations of hepatic transaminases in patients treated with Tecfidera relative to placebo was primarily seen during the first 6&nbsp;months of treatment. Elevations of alanine aminotransferase and aspartate aminotransferase &ge; 3&nbsp;times ULN, respectively, were seen in 5%&nbsp;and 2%&nbsp;of patients treated with placebo and 6%&nbsp;and 2%&nbsp;of patients treated with Tecfidera. Discontinuations due to elevated hepatic transaminases were &lt; 1%&nbsp;and similar in patients treated with Tecfidera or placebo. Elevations in transaminases &ge; 3&nbsp;times ULN with concomitant elevations in total bilirubin &gt; 2&nbsp;times ULN, were not observed in placebo-controlled studies.</p><p>&nbsp;</p><p>Increase of liver enzymes and cases of drug-induced liver injury (elevations in transaminases &ge;3&nbsp;times ULN with concomitant elevations in total bilirubin &gt; 2&nbsp;times ULN), have been reported in post marketing experience following Tecfidera administration, which resolved upon treatment discontinuation.</p><p>&nbsp;</p><p><em>Lymphopenia </em></p><p>&nbsp;</p><p>In the placebo-controlled studies most patients (&gt; 98%) had normal lymphocyte values prior to initiating treatment. Upon treatment with Tecfidera, mean lymphocyte counts decreased over the first year with a subsequent plateau. On average, lymphocyte counts decreased by approximately 30% of baseline value. Mean and median lymphocyte counts remained within normal limits.&nbsp; Lymphocyte counts &lt; 0.5 x 10<sup>9</sup>/L were observed in &lt; 1% of patients treated with placebo and 6% of patients treated with Tecfidera. A lymphocyte count &lt; 0.2 x 10<sup>9</sup>/L was observed in 1 patient treated with Tecfidera and in no patients treated with placebo.</p><p>&nbsp;</p><p>In clinical studies (both controlled and uncontrolled), 41% of patients treated with Tecfidera had lymphopenia (defined in these studies as &lt; 0.91 x 10<sup>9</sup>/L). Mild lymphopenia (counts &ge; 0.8 x 10<sup>9</sup>/L to &lt; 0.91 x 10<sup>9</sup>/L) was observed in 28% of patients; moderate lymphopenia (counts &ge; 0.5 x 10<sup>9</sup>/L to &lt; 0.8 x 10<sup>9</sup>/L) persisting for at least six months was observed in 11% of patients; severe lymphopenia (counts &lt; 0.5 x 10<sup>9</sup>/L) persisting for at least six months was observed in 2% of patients. In the group with severe lymphopenia, the majority of lymphocyte counts remained &lt; 0.5x 10<sup>9</sup>/L with continued therapy.</p><p>&nbsp;</p><p>In addition, in an uncontrolled, prospective, post-marketing study, at week 48 of treatment with Tecfidera (n=185)<em> </em>CD4+ T&nbsp;cells were moderately (counts &ge; 0.2 x 10<sup>9</sup>/L to &lt; 0.4 x 10<sup>9</sup>/L) or severely (&lt; 0.2 x 10<sup>9</sup>/L) decreased in up to 37&nbsp;% or 6&nbsp;% of patients, respectively, while CD8+ T&nbsp;cells were more frequently reduced with up to 59&nbsp;% of patients at counts &lt;0.2 x 10<sup>9</sup>/L and 25&nbsp;% of patients at counts &lt; 0.1 x 10<sup>9</sup>/L.</p><p>In controlled and uncontrolled clinical studies, patients who discontinued Tecfidera therapy with lymphocyte counts below the lower limit of normal (LLN) were monitored for recovery of lymphocyte count to the LLN (see section 5.1).</p><p>&nbsp;</p><p><em>Infections, including PML and opportunistic infections</em></p><p>&nbsp;</p><p>Cases of infections with John Cunningham virus (JCV) causing Progressive Multifocal Leukoencephalopathy (PML) have been reported with Tecfidera (see section 4.4). PML may be fatal or result in severe disability. In one of the clinical trials, one patient taking Tecfidera developed PML in the setting of prolonged severe lymphopenia (lymphocyte counts predominantly &lt; 0.5 x 10<sup>9</sup>/L for 3.5 years), with a fatal outcome. In the post-marketing setting, PML has also occurred in the presence of moderate and mild lymphopenia (&gt; 0.5 x 10<sup>9</sup>/L to &lt; LLN, as defined by local laboratory reference range).</p><p>&nbsp;</p><p>In several PML cases with determination of T&nbsp;cell subsets at the time of diagnosis of PML, CD8+ T&nbsp;cell counts were found to be decreased to &lt; 0.1 x 10<sup>9</sup>/L, whereas reductions in CD4+ T&nbsp;cells counts were variable (ranging from &lt; 0.05 to 0.5 x 10<sup>9</sup>/L) and correlated more with the overall severity of lymphopenia (&lt; 0.5 x 10<sup>9</sup>/L to &lt; LLN). Consequently, the CD4+/CD8+ ratio was increased in these patients.</p><p>&nbsp;</p><p>Prolonged moderate to severe lymphopenia appears to increase the risk of PML with Tecfidera, however, PML also occurred in patients with mild lymphopenia. Additionally, the majority of PML cases in the post-marketing setting have occurred in patients &gt; 50 years.</p><p>&nbsp;</p><p>Herpes zoster infections have been reported with Tecfidera use. In an ongoing long-term extension study, in which 1,736 MS patients are treated with Tecfidera, approximately 5% experienced one or more events of herpes zoster, the majority of which were mild to moderate in severity. Most subjects, including those who experienced a serious herpes zoster infection, had lymphocyte counts above the lower limit of normal. In a majority of subjects with concurrent lymphocyte counts below the LLN, lymphopenia was rated moderate or severe.&nbsp; In the post-marketing setting, most cases of herpes zoster infection were non-serious and resolved with treatment.&nbsp; Limited data is available on absolute lymphocyte count (ALC) in patients with herpes zoster infection in the post-marketing setting. However, when reported, most patients experienced moderate (&ge; 0.5 x 10<sup>9</sup>/L to &lt; 0.8 x 10<sup>9</sup>/L) or severe (&lt; 0.5 x 10<sup>9</sup>/L to 0.2 x 10<sup>9</sup>/L) lymphopenia (see section 4.4).</p><p><em>Laboratory abnormalities</em></p><p>&nbsp;</p><p>In the placebo-controlled studies, measurement of urinary ketones (1+ or greater) was higher in patients treated with Tecfidera (45%) compared to placebo (10%). No untoward clinical consequences were observed in clinical trials.</p><p>&nbsp;</p><p>Levels of&nbsp;1,25-dihydroxyvitamin D decreased in Tecfidera treated patients relative to placebo (median percentage decrease from baseline at 2 years of 25%&nbsp;versus&nbsp;15%, respectively) and levels of parathyroid hormone (PTH) increased in Tecfidera treated patients relative to placebo (median percentage increase from baseline at 2 years of 29%&nbsp;versus&nbsp;15%,&nbsp;respectively). Mean values for both parameters remained within normal range.</p><p>&nbsp;</p><p>A transient increase in mean eosinophil counts was seen during the first 2&nbsp;months of therapy.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>&nbsp;</p><p>In a 96&nbsp;week open label, randomised active controlled trial in paediatric patients with RRMS aged&nbsp;10 to less than 18&nbsp;years (120&nbsp;mg twice a day for 7&nbsp;days followed by 240&nbsp;mg twice a day for the remainder of treatment; study population, n=78), the safety profile in paediatric patients appeared similar to that previously observed in adult patients.</p><p>&nbsp;</p><p>The paediatric clinical trial design differed from the adult placebo-controlled clinical trials. Therefore, a contribution of clinical trial design to numerical differences in adverse reactions between the paediatric and adult populations, cannot be excluded.</p><p>&nbsp;</p><p>The following adverse events were more frequently reported (&ge; 10%) in the paediatric population than in the adult population:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headache was reported in 28% of patients treated with Tecfidera versus 36% in patients treated with interferon beta-1a.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Gastrointestinal disorders were reported in 74% of patients treated with Tecfidera versus 31% in patients treated with interferon beta-1a. Among them, abdominal pain and vomiting were the most frequently reported with Tecfidera.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Respiratory, thoracic and mediastinal disorders were reported in 32% of patients treated with Tecfidera versus 11% in patients treated with interferon beta-1a. Among them, oropharyngeal pain and cough were the most frequently reported with Tecfidera.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dysmenorrhea was reported in 17% of patients treated with Tecfidera versus 7% of patients treated with interferon beta‑1a.</p><p>&nbsp;</p><p>In a small 24-week open-label uncontrolled study in paediatric patients with RRMS aged 13 to 17&nbsp;years (120&nbsp;mg twice a day for 7&nbsp;days followed by 240&nbsp;mg twice a day for the remainder of treatment; safety population, n=22), followed by a 96&nbsp;week extension study (240&nbsp;mg twice per day; safety population n=20), the safety profile appeared similar to that observed in adult patients.&nbsp;</p><p>&nbsp;</p><p>There are limited data available in children between 10 and 12&nbsp;years old. The safety and efficacy of Tecfidera in children aged less than 10&nbsp;years have not yet been established.</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p><u>&nbsp;</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p>Cases of overdose with Tecfidera have been reported. The symptoms described in these cases were consistent with the known adverse reaction profile of Tecfidera. There are no known therapeutic interventions to enhance elimination of Tecfidera nor is there a known antidote. In the event of overdose, it is recommended that symptomatic supportive treatment be initiated as clinically indicated.</p><p>&nbsp;</p><p><strong>To report any side effect (s):</strong></p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia:</strong></p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The National Pharmacovigilance Centre (NPC):</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SFDA Call Center: 19999</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa</p><p>&nbsp;</p><ul><li><strong>Other GCC States:</strong></li></ul><p>- &nbsp;&nbsp;&nbsp;&nbsp;<em>Please contact the relevant competent authority.</em></p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p>Pharmacotherapeutic group: Immunosuppressants, other immunosuppressants, ATC code: L04AX07</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>&nbsp;</p><p>The mechanism by which dimethyl fumarate exerts therapeutic effects in multiple sclerosis is not fully understood. Preclinical studies indicate that dimethyl fumarate pharmacodynamic responses appear to be primarily mediated through activation of the Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) transcriptional pathway. Dimethyl fumarate has been shown to up regulate Nrf2-dependent antioxidant genes in patients (e.g. NAD(P)H dehydrogenase, quinone 1; [NQO1]).</p><p>&nbsp;</p><p><u>Pharmacodynamic effects</u></p><p>&nbsp;</p><p><em>Effects on the immune system</em></p><p><em>&nbsp;</em></p><p>In preclinical and clinical studies, dimethyl fumarate demonstrated anti-inflammatory and immunomodulatory properties. Dimethyl fumarate and monomethyl fumarate, the primary metabolite of dimethyl fumarate, significantly reduced immune cell activation and subsequent release of pro-inflammatory cytokines in response to inflammatory stimuli in preclinical models. In clinical studies with psoriasis patients, dimethyl fumarate affected lymphocyte phenotypes through a down-regulation of pro-inflammatory cytokine profiles (T<sub>H</sub>1, T<sub>H</sub>17), and biased towards anti-inflammatory production (T<sub>H</sub>2). Dimethyl fumarate demonstrated therapeutic activity in multiple models of inflammatory and neuroinflammatory injury. In Phase 3 studies in MS patients (DEFINE, CONFIRM and ENDORSE), upon treatment with Tecfidera mean lymphocyte counts decreased on average by approximately 30% of their baseline value over the first year with a subsequent plateau. In these studies, patients who discontinued Tecfidera therapy with lymphocyte counts below the lower limit of normal (LLN, 910&nbsp;cells/mm<sup>3</sup>) were monitored for recovery of lymphocyte counts to the LLN.</p><p>&nbsp;</p><p>Figure 1 shows the proportion of patients estimated to reach the LLN based on the Kaplan-Meier method without prolonged severe lymphopenia. The recovery baseline (RBL) was defined as the last on-treatment ALC prior to Tecfidera discontinuation. The estimated proportion of patients recovering to LLN (ALC &ge;&nbsp;0.9&nbsp;x&nbsp;10<sup>9</sup>/L) at Week&nbsp;12 and Week&nbsp;24, who had mild, moderate, or severe lymphopenia at RBL are presented in Table&nbsp;1, Table&nbsp;2, and Table&nbsp;3 with 95% pointwise confidence intervals. The standard error of the Kaplan-Meier estimator of the survival function is computed using Greenwood&rsquo;s formula.</p><p><strong>Figure 1:</strong> <strong>Kaplan-Meier Method; Proportion of Patients with Recovery to </strong><strong>&ge; </strong><strong>910 cells/mm<sup>3</sup> LLN from the Recovery Baseline (RBL)</strong></p><p>&nbsp;</p><p>&nbsp;</p><p><strong><u>Table 1:</u></strong><u> </u><strong><u>Kaplan-Meier Method; Proportion of patients estimated to reach LLN, mild lymphopenia at the recovery baseline (RBL), excluding patients with prolonged severe lymphopenia</u></strong></p><p><u>&nbsp;</u></p><table cellspacing="0" cellpadding="0" border="1"><tbody><tr><td style="vertical-align:top"><p><strong><u>Number of patients with mild lymphopenia<sup>a</sup> at risk</u></strong></p></td><td style="vertical-align:top"><p><strong><u>Baseline</u></strong></p><p><strong><u>N=86</u></strong></p></td><td style="vertical-align:top"><p><strong><u>Week&nbsp;12</u></strong></p><p><strong><u>N=12</u></strong></p></td><td style="vertical-align:top"><p><strong><u>Week&nbsp;24</u></strong></p><p><strong><u>N=4</u></strong></p></td></tr><tr><td style="vertical-align:top"><p><u>Proportion reaching</u></p><p><u>LLN (95% CI)</u></p></td><td style="vertical-align:top"><p><u>&nbsp;</u></p></td><td style="vertical-align:top"><p><u>0.81</u></p><p><u>(0.71, 0.89)</u></p></td><td style="vertical-align:top"><p><u>0.90</u></p><p><u>(0.81, 0.96)</u></p></td></tr></tbody></table><p><u><sup>a</sup></u><u> Patients with ALC&nbsp;&lt;&nbsp;910 and &ge;&nbsp;800 cells/mm<sup>3</sup> at RBL, excluding patients with prolonged severe lymphopenia.</u></p><p><u>&nbsp;</u></p><p><strong><u>Table 2:</u></strong><u> </u><strong><u>Kaplan-Meier Method; Proportion of patients estimated to reach LLN, moderate lymphopenia at the recovery baseline (RBL), excluding patients with prolonged severe lymphopenia</u></strong></p><p><u>&nbsp;</u></p><table cellspacing="0" cellpadding="0" border="1" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong><u>Number of patients with moderate lymphopenia<sup>a</sup> at risk</u></strong></p></td><td style="vertical-align:top"><p><strong><u>Baseline</u></strong></p><p><strong><u>N=124</u></strong></p></td><td style="vertical-align:top"><p><strong><u>Week&nbsp;12</u></strong></p><p><strong><u>N=33</u></strong></p></td><td style="vertical-align:top"><p><strong><u>Week&nbsp;24</u></strong></p><p><strong><u>N=17</u></strong></p></td></tr><tr><td style="vertical-align:top"><p><u>Proportion reaching</u></p><p><u>LLN (95% CI)</u></p></td><td style="vertical-align:top"><p><u>&nbsp;</u></p></td><td style="vertical-align:top"><p><u>0.57</u></p><p><u>(0.46, 0.67)</u></p></td><td style="vertical-align:top"><p><u>0.70</u></p><p><u>(0.60, 0.80)</u></p></td></tr></tbody></table><p><u><sup>a</sup></u><u> Patients with ALC&nbsp;&lt;&nbsp;800 and &ge;&nbsp;500 cells/mm<sup>3</sup> at RBL, excluding patients with prolonged severe lymphopenia.</u></p><p><u>&nbsp;</u></p><p><strong><u>Table 3:</u></strong><u> </u><strong><u>Kaplan-Meier Method; Proportion of patients estimated to reach LLN, severe lymphopenia at the recovery baseline (RBL), excluding patients with prolonged severe lymphopenia</u></strong></p><p><u>&nbsp;</u></p><table cellspacing="0" cellpadding="0" border="1"><tbody><tr><td style="vertical-align:top"><p><strong><u>Number of patients with severe lymphopenia<sup>a</sup> at risk</u></strong></p></td><td style="vertical-align:top"><p><strong><u>Baseline</u></strong></p><p><strong><u>N=18</u></strong></p></td><td style="vertical-align:top"><p><strong><u>Week&nbsp;12</u></strong></p><p><strong><u>N=6</u></strong></p></td><td style="vertical-align:top"><p><strong><u>Week&nbsp;24</u></strong></p><p><strong><u>N=4</u></strong></p></td></tr><tr><td style="vertical-align:top"><p><u>Proportion reaching</u></p><p><u>LLN (95% CI)</u></p></td><td style="vertical-align:top"><p><u>&nbsp;</u></p></td><td style="vertical-align:top"><p><u>0.43</u></p><p><u>(0.20, 0.75)</u></p></td><td style="vertical-align:top"><p><u>0.62</u></p><p><u>(0.35, 0.88)</u></p></td></tr></tbody></table><p><u><sup>a</sup></u><u> Patients with ALC&nbsp;&lt;&nbsp;500 cells/mm<sup>3</sup> at RBL, excluding patients with prolonged severe lymphopenia.</u></p><p><u>&nbsp;</u></p><p><u>Clinical efficacy and safety</u></p><p>&nbsp;</p><p>Two, 2-year, randomised, double-blind, placebo-controlled studies DEFINE with 1,234&nbsp;patients and CONFIRM with 1,417&nbsp;patients of patients with relapsing-remitting multiple sclerosis (RRMS) were performed. Patients with progressive forms of MS were not included in these studies.</p><p>&nbsp;</p><p>Efficacy (see table below) and safety were demonstrated in patients with Expanded Disability Status Scale (EDSS) scores ranging from 0&nbsp;to 5&nbsp;inclusive, who had experienced at least 1&nbsp;relapse during the year prior to randomisation, or, in the 6&nbsp;weeks before randomisation had a brain Magnetic Resonance Imaging (MRI) demonstrating at least one gadolinium-enhancing (Gd+) lesion. Study&nbsp;CONFIRM contained a rater-blinded (i.e. study physician/ investigator assessing the response to study treatment was blinded) reference comparator of glatiramer acetate.</p><p>&nbsp;</p><p>In DEFINE, patients had the following median baseline characteristics: age 39&nbsp;years, disease duration 7.0&nbsp;years, EDSS score&nbsp;2.0. In addition, 16%&nbsp;of patients had an EDSS score &gt; 3.5, 28% had &ge; 2&nbsp;relapses in the prior year and 42% had previously received other approved MS treatments. In the MRI cohort 36% of patients entering the study had Gd+ lesions at baseline (mean number of Gd+ lesions 1.4).</p><p>&nbsp;</p><p>In CONFIRM, patients had the following median baseline characteristics: age 37&nbsp;years, disease duration&nbsp;6.0 years, EDSS score&nbsp;2.5. In addition, 17%&nbsp;of patients had an EDSS score &gt; 3.5, 32%&nbsp;had &ge; 2&nbsp;relapses in the prior year and 30% had previously received other approved MS treatments. In the MRI cohort 45%&nbsp;of patients entering the study had Gd+ lesions at baseline (mean number of Gd+ lesions&nbsp;2.4).</p><p>&nbsp;</p><p>Compared to placebo, patients treated with Tecfidera had a clinically meaningful and statistically significant reduction on the primary endpoint in study&nbsp;DEFINE, proportion of patients relapsed at 2&nbsp;years; and the primary endpoint in study&nbsp;CONFIRM, annualised relapse rate (ARR) at 2&nbsp;years.</p><p>&nbsp;</p><p>The ARR for glatiramer acetate and placebo was 0.286 and 0.401 respectively in study&nbsp;CONFIRM, corresponding to a reduction of 29% (p=0.013), which is consistent with approved prescribing information.</p><p>&nbsp;</p><table cellspacing="0" cellpadding="0" border="1" style="width:597px"><thead><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td colspan="2"><p><strong>DEFINE</strong></p></td><td colspan="3"><p><strong>CONFIRM</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p></td><td style="vertical-align:top"><p><strong>Tecfidera</strong></p><p><strong>240&nbsp;mg </strong></p><p><strong>twice a day</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p></td><td style="vertical-align:top"><p><strong>Tecfidera</strong></p><p><strong>240 mg</strong></p><p><strong>twice a day</strong></p></td><td style="vertical-align:top"><p><strong>Glatiramer acetate</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p><strong>Clinical Endpoints<sup>a</sup></strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>No. patients</p></td><td style="vertical-align:top"><p>408</p></td><td style="vertical-align:top"><p>410</p></td><td style="vertical-align:top"><p>363</p></td><td style="vertical-align:top"><p>359</p></td><td style="vertical-align:top"><p>350</p></td></tr><tr><td style="vertical-align:top"><p>Annualised relapse rate</p></td><td style="vertical-align:top"><p>0.364</p></td><td style="vertical-align:top"><p>0.172***</p></td><td style="vertical-align:top"><p>0.401</p></td><td style="vertical-align:top"><p>0.224***</p></td><td style="vertical-align:top"><p>0.286*</p></td></tr><tr><td style="vertical-align:top"><p>Rate ratio</p><p>(95% CI)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.47</p><p>(0.37, 0.61)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.56</p><p>(0.42, 0.74)</p></td><td style="vertical-align:top"><p>0.71</p><p>(0.55, 0.93)</p></td></tr><tr><td style="vertical-align:top"><p>Proportion relapsed</p></td><td style="vertical-align:top"><p>0.461</p></td><td style="vertical-align:top"><p>0.270***</p></td><td style="vertical-align:top"><p>0.410</p></td><td style="vertical-align:top"><p>0.291**</p></td><td style="vertical-align:top"><p>0.321**</p></td></tr><tr><td style="vertical-align:top"><p>Hazard ratio</p><p>(95% CI)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.51</p><p>(0.40, 0.66)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.66</p><p>(0.51, 0.86)</p></td><td style="vertical-align:top"><p>0.71</p><p>(0.55, 0.92)</p></td></tr><tr><td style="vertical-align:top"><p>Proportion with 12-week confirmed disability progression</p></td><td style="vertical-align:top"><p>0.271</p></td><td style="vertical-align:top"><p>0.164**</p></td><td style="vertical-align:top"><p>0.169</p></td><td style="vertical-align:top"><p>0.128<sup>#</sup></p></td><td style="vertical-align:top"><p>0.156<sup>#</sup></p></td></tr><tr><td style="vertical-align:top"><p>Hazard ratio</p><p>(95% CI)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.62</p><p>(0.44, 0.87)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.79</p><p>(0.52, 1.19)</p></td><td style="vertical-align:top"><p>0.93</p><p>(0.63, 1.37)</p></td></tr><tr><td style="vertical-align:top"><p>Proportion with 24&nbsp;week confirmed disability progression</p></td><td style="vertical-align:top"><p>0.169</p></td><td style="vertical-align:top"><p>0.128#</p></td><td style="vertical-align:top"><p>0.125</p></td><td style="vertical-align:top"><p>0.078#</p></td><td style="vertical-align:top"><p>0.108#</p></td></tr><tr><td style="vertical-align:top"><p>Hazard ratio</p><p>(95% CI)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.77<br />(0.52, 1.14)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.62<br />(0.37, 1.03)</p></td><td style="vertical-align:top"><p>0.87</p><p>(0.55, 1.38)</p></td></tr><tr><td style="vertical-align:top"><p><strong>MRI Endpoints</strong><sup>b</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>No. patients</p></td><td style="vertical-align:top"><p>165</p></td><td style="vertical-align:top"><p>152</p></td><td style="vertical-align:top"><p>144</p></td><td style="vertical-align:top"><p>147</p></td><td style="vertical-align:top"><p>161</p></td></tr><tr><td style="vertical-align:top"><p>Mean (median) number of new or newly enlarging T2 lesions over 2&nbsp;years</p></td><td style="vertical-align:top"><p>16.5</p><p>(7.0)</p></td><td style="vertical-align:top"><p>3.2</p><p>(1.0)***</p></td><td style="vertical-align:top"><p>19.9</p><p>(11.0)</p></td><td style="vertical-align:top"><p>5.7</p><p>(2.0)***</p></td><td style="vertical-align:top"><p>9.6</p><p>(3.0)***</p></td></tr><tr><td style="vertical-align:top"><p>Lesion mean ratio</p><p>(95% CI)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.15</p><p>(0.10, 0.23)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.29</p><p>(0.21, 0.41)</p></td><td style="vertical-align:top"><p>0.46</p><p>(0.33, 0.63)</p></td></tr><tr><td style="vertical-align:top"><p>Mean (median) number of Gd lesions at 2&nbsp;years</p></td><td style="vertical-align:top"><p>1.8</p><p>(0)</p></td><td style="vertical-align:top"><p>0.1</p><p>(0)***</p></td><td style="vertical-align:top"><p>2.0</p><p>(0.0)</p></td><td style="vertical-align:top"><p>0.5</p><p>(0.0)***</p></td><td style="vertical-align:top"><p>0.7</p><p>(0.0)**</p></td></tr><tr><td style="vertical-align:top"><p>Odds ratio</p><p>(95% CI)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.10</p><p>(0.05, 0.22)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.26</p><p>(0.15, 0.46)</p></td><td style="vertical-align:top"><p>0.39</p><p>(0.24, 0.65)</p></td></tr><tr><td style="vertical-align:top"><p>Mean (median) number of new T1 hypointense lesions over 2&nbsp;years</p></td><td style="vertical-align:top"><p>5.7</p><p>(2.0)</p></td><td style="vertical-align:top"><p>2.0</p><p>(1.0)***</p></td><td style="vertical-align:top"><p>8.1</p><p>(4.0)</p></td><td style="vertical-align:top"><p>3.8</p><p>(1.0)***</p></td><td style="vertical-align:top"><p>4.5</p><p>(2.0)**</p></td></tr><tr><td style="vertical-align:top"><p>Lesion mean ratio</p><p>(95% CI)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.28</p><p>(0.20, 0.39)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.43</p><p>(0.30, 0.61)</p></td><td style="vertical-align:top"><p>0.59</p><p>(0.42, 0.82)</p></td></tr></tbody></table><p><sup>a</sup>All analyses of clinical endpoints were intent-to-treat; <sup>b</sup>MRI analysis used MRI cohort</p><p>*P-value &lt; 0.05; **P-value &lt; 0.01; ***P-value &lt; 0.0001; #not statistically significant</p><p>&nbsp;</p><p>An open non-controlled 8-year extension study (ENDORSE) enrolled 1,736 eligible RRMS patients from the pivotal studies (DEFINE and CONFIRM). The primary objective of the study was to assess the long-term safety of Tecfidera in patients with RRMS. Of the 1,736&nbsp;patients, approximately half (909,&nbsp;52%) were treated for 6&nbsp;years or longer. 501&nbsp;patients were continuously treated with Tecfidera 240&nbsp;mg twice daily across all 3&nbsp;studies and 249&nbsp;patients who were previously treated with placebo in studies&nbsp;DEFINE and CONFIRM received treatment 240&nbsp;mg twice daily in study&nbsp;ENDORSE. Patients who received treatment twice daily continuously were treated for up to 12&nbsp;years.</p><p>&nbsp;</p><p>During study&nbsp;ENDORSE, more than half of all patients treated with Tecfidera 240&nbsp;mg twice daily did not have a relapse. For patients continuously treated twice daily across all 3&nbsp;studies, the adjusted ARR was 0.187 (95% CI: 0.156, 0.224) in studies DEFINE and CONFIRM and 0.141&nbsp;(95%&nbsp;CI:&nbsp;0.119,&nbsp;0.167) in study ENDORSE.&nbsp; For patients previously treated with placebo, the adjusted ARR decreased from 0.330&nbsp;(95%&nbsp;CI:&nbsp;0.266,&nbsp;0.408) in studies&nbsp;DEFINE and CONFIRM&nbsp;to&nbsp;0.149&nbsp;(95%&nbsp;CI:&nbsp;0.116,&nbsp;0.190) in study&nbsp;ENDORSE.</p><p>&nbsp;</p><p>In study&nbsp;ENDORSE, the majority of patients&nbsp;(&gt;&nbsp;75%) did not have confirmed disability progression (measured as 6-month sustained disability progression). Pooled results from the three studies demonstrated Tecfidera treated patients had consistent and low rates of confirmed disability progression with slight increase in mean EDSS scores across ENDORSE. MRI assessments (up to year&nbsp;6, including 752&nbsp;patients who had previously been included in the MRI cohort of studies DEFINE and CONFIRM showed that the majority of patients (approximately&nbsp;90%) had no Gd-enhancing lesions. Over the 6&nbsp;years, the annual adjusted mean number of new or newly enlarging T2 and new T1 lesions remained low.</p><p>&nbsp;</p><p>Efficacy in patients with high disease activity:</p><p>In studies DEFINE and CONFIRM, consistent treatment effect on relapses in a subgroup of patients with high disease activity was observed, whilst the effect on time to 3-month sustained disability progression was not clearly established. Due to the design of the studies, high disease activity was defined as follows:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Patients with 2 or more relapses in one year, and with one or more Gd-enhancing lesions on brain MRI (n=42 in DEFINE; n=51 in CONFIRM) or,</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Patients who have failed to respond to a full and adequate course (at least one year of treatment) of beta-interferon, having had at least 1 relapse in the previous year while on therapy, and at least 9 T2-hyperintense lesions in cranial MRI or at least 1 Gd-enhancing lesion, or patients having an unchanged or increased relapse rate in the prior year as compared to the previous 2 years (n=177 in DEFINE; n=141 in CONFIRM).</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p><u>&nbsp;</u></p><p>The safety and effectiveness of Tecfidera in paediatric RRMS was evaluated in a randomised, open-label, active-controlled (interferon beta-1a) parallel group study in patients with RRMS aged 10 to less than 18&nbsp;years of age. One hundred and fifty patients were randomised to dimethyl fumarate (240&nbsp;mg BID oral) or interferon beta-1a (30&nbsp;&mu;g&nbsp;IM once a week) for 96&nbsp;weeks. The primary endpoint was the proportion of patients free of new or newly enlarging T2 hyperintense lesions on brain MRI scans at week&nbsp;96. The main secondary endpoint was the number of new or newly enlarging T2 hyperintense lesions on brain MRI scans at week&nbsp;96. Descriptive statistics are presented as no confirmatory hypothesis was pre-planned for the primary endpoint.</p><p>&nbsp;</p><p>The proportion of patients in the ITT population with no new or newly enlarging T2 MRI lesions at week&nbsp;96 relative to baseline was 12.8% for dimethyl fumarate versus 2.8% in the interferon beta-1a group. The mean number of new or newly enlarging T2 lesions at Week&nbsp;96 relative to baseline, adjusted for baseline number of T2 lesions and age (ITT population excluding patients without MRI measurements) was 12.4 for dimethyl fumarate and 32.6 for interferon beta-1a.</p><p>The probability for clinical relapse was 34% in the dimethyl fumarate group and 48% in the interferon beta-1a group by the end of the 96&nbsp;week open-label study period.</p><p>&nbsp;</p><p>The safety profile in paediatric patients (aged 13 to less than 18&nbsp;years of age) receiving Tecfidera was qualitatively consistent with that previously observed in adult patients (see section 4.8)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p>Orally administered dimethyl fumarate undergoes rapid presystemic hydrolysis by esterases and is converted to its primary metabolite, monomethyl fumarate, which is also active. Dimethyl fumarate is not quantifiable in plasma following oral administration of Tecfidera. Therefore, all pharmacokinetic analyses related to dimethyl fumarate were performed with plasma monomethyl fumarate concentrations. Pharmacokinetic data were obtained in subjects with multiple sclerosis and healthy volunteers.</p><p>&nbsp;</p><p><u>Absorption</u></p><p>&nbsp;</p><p>The T<sub>max</sub> of monomethyl fumarate is 2&nbsp;to 2.5&nbsp;hours. As Tecfidera gastro-resistant hard capsules contain microtablets, which are protected by an enteric coating, absorption does not commence until they leave the stomach (generally less than 1&nbsp;hour). Following 240&nbsp;mg twice a day administered with food, the median peak (C<sub>max</sub>) was 1.72&nbsp;mg/L and overall area under the curve (AUC) exposure was 8.02&nbsp;h.mg/L in subjects with multiple sclerosis. Overall, C<sub>max</sub> and AUC increased approximately dose- proportionally in the dose range studied (120&nbsp;mg to 360&nbsp;mg). In subjects with multiple sclerosis, two 240&nbsp;mg doses were administered 4&nbsp;hours apart as part of a three times a day dosing regimen. This resulted in a minimal accumulation of exposure yielding an increase in the median Cmax of 12% compared to the twice daily dosing (1.72&nbsp;mg/L for twice daily compared to 1.93&nbsp;mg/L for three times daily) with no safety implications.</p><p>&nbsp;</p><p>Food does not have a clinically significant effect on exposure of dimethyl fumarate. However, Tecfidera should be taken with food due to improved tolerability with respect to flushing or gastrointestinal adverse events (see section&nbsp;4.2).</p><p>&nbsp;</p><p><u>Distribution</u></p><p>&nbsp;</p><p>The apparent volume of distribution following oral administration of 240&nbsp;mg dimethyl fumarate varies between 60&nbsp;L and 90&nbsp;L. Human plasma protein binding of monomethyl fumarate generally ranges between 27%&nbsp;and 40%.</p><p>&nbsp;</p><p><u>Biotransformation</u></p><p>&nbsp;</p><p>In humans, dimethyl fumarate is extensively metabolised with less than 0.1% of the dose excreted as unchanged dimethyl fumarate in urine. It is initially metabolised by esterases, which are ubiquitous in the gastrointestinal tract, blood and tissues, before it reaches the systemic circulation. Further metabolism occurs through the tricarboxylic acid cycle, with no involvement of the cytochrome P450 (CYP) system. A single 240&nbsp;mg <sup>14</sup>C-dimethyl fumarate dose study identified glucose as the predominant metabolite in human plasma. Other circulating metabolites included fumaric acid, citric acid and monomethyl fumarate. The downstream metabolism of fumaric acid occurs through the tricarboxylic acid cycle, with exhalation of CO<sub>2</sub> serving as a primary route of elimination.</p><p>&nbsp;</p><p><u>Elimination</u></p><p>&nbsp;</p><p>Exhalation of CO<sub>2</sub> is the primary route of dimethyl fumarate elimination accounting for 60% of the dose. Renal and faecal elimination are secondary routes of elimination, accounting for 15.5% and 0.9% of the dose respectively.</p><p>&nbsp;</p><p>The terminal half-life of monomethyl fumarate is short (approximately 1&nbsp;hour) and no circulating monomethyl fumarate is present at 24&nbsp;hours in the majority of individuals. Accumulation of parent drug or monomethyl fumarate does not occur with multiple doses of dimethyl fumarate at the therapeutic regimen.</p><p>&nbsp;</p><p><u>Linearity</u></p><p>&nbsp;</p><p>Dimethyl fumarate exposure increases in an approximately dose proportional manner with single and multiple doses in the 120&nbsp;mg to 360&nbsp;mg dose range studied.</p><p>&nbsp;</p><p><u>Pharmacokinetics in special patient groups</u></p><p>&nbsp;</p><p>Based on the results of Analysis of Variance (ANOVA), body weight is the main covariate of exposure (by C<sub>max</sub> and AUC) in RRMS subjects, but did not affect safety and efficacy measures evaluated in the clinical studies.</p><p>&nbsp;</p><p>Gender and age did not have a clinically significant impact on the pharmacokinetics of dimethyl fumarate. The pharmacokinetics in patients aged&nbsp;65&nbsp;and over has not been studied.</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p><em>&nbsp;</em></p><p>The pharmacokinetic profile of 240 mg dimethyl fumarate twice a day was evaluated in a small, open-label, uncontrolled study in patients with RRMS aged 13 to 17 years (n=21). The pharmacokinetics of Tecfidera in these adolescent patients was consistent with that previously observed in adult patients (C<sub>max</sub>: 2.00&plusmn;1.29&nbsp;mg/L; AUC<sub>0-12hr</sub>: 3.62&plusmn;1.16 h.mg/L, which corresponds to an overall daily AUC of 7.24&nbsp;h.mg/L).</p><p>&nbsp;</p><p><em>Renal impairment</em></p><p><em>&nbsp;</em></p><p>Since the renal pathway is a secondary route of elimination for dimethyl fumarate accounting for less than 16%&nbsp;of the dose administered, evaluation of pharmacokinetics in individuals with renal impairment was not conducted.</p><p>&nbsp;</p><p><em>Hepatic impairment</em></p><p><em>&nbsp;</em></p><p>As dimethyl fumarate and monomethyl fumarate are metabolised by esterases, without the involvement of the CYP450 system, evaluation of pharmacokinetics in individuals with hepatic impairment was not conducted.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p>The adverse reactions described in the Toxicology and Reproduction toxicity sections below were not observed in clinical studies, but were seen in animals at exposure levels similar to clinical exposure levels.</p><p>&nbsp;</p><p><u>&nbsp;</u></p><p><u>Mutagenesis </u></p><p>&nbsp;</p><p>Dimethyl fumarate and mono-methylfumarate were negative in a battery of <em>in vitro</em> assays (Ames, chromosomal aberration in mammalian cells). Dimethyl fumarate was negative in the <em>in vivo</em> micronucleus assay in the rat.</p><p>&nbsp;</p><p><u>Carcinogenesis</u></p><p>&nbsp;</p><p>Carcinogenicity studies of dimethyl fumarate were conducted for up to 2&nbsp;years in mice and rats. Dimethyl fumarate was administered orally at doses of 25,&nbsp;75,&nbsp;200 and&nbsp;400&nbsp;mg/kg/day in mice, and at doses of 25, 50, 100, and 150&nbsp;mg/kg/day in rats. In mice, the incidence of renal tubular carcinoma was increased at 75&nbsp;mg/kg/day, at equivalent exposure (AUC) to the recommended human dose. In rats, the incidence of renal tubular carcinoma and testicular Leydig cell adenoma was increased at 100&nbsp;mg/kg/day, approximately 2&nbsp;times higher exposure than the recommended human dose. The relevance of these findings to human risk is unknown.</p><p>&nbsp;</p><p>The incidence of squamous cell papilloma and carcinoma in the nonglandular stomach (forestomach) was increased at equivalent exposure to the recommended human dose in mice and below exposure to the recommended human dose in rats (based on AUC). The forestomach in rodents does not have a human counterpart.</p><p>&nbsp;</p><p><u>Toxicology</u></p><p>&nbsp;</p><p>Nonclinical studies in rodent, rabbits, and monkeys were conducted with a dimethyl fumarate suspension (dimethyl fumarate in 0.8%&nbsp;hydroxypropyl methylcellulose) administered by oral gavage. The chronic dog study was conducted with oral administration of the dimethyl fumarate capsule.</p><p>&nbsp;</p><p>Kidney changes were observed after repeated oral administration of dimethyl fumarate in mice, rats, dogs, and monkeys. Renal tubule epithelial regeneration, suggestive of injury, was observed in all species. Renal tubular hyperplasia was observed in rats with life time dosing (2‑year study). In dogs that received daily oral doses of dimethyl fumarate for 11 months, the margin calculated for cortical atrophy was observed at 3 times the recommended dose based on AUC. In monkeys that received daily oral doses of dimethyl fumarate for 12 months, single cell necrosis was observed at 2 times the recommended dose based on AUC. Interstitial fibrosis and cortical atrophy were observed at 6&nbsp;times the recommended dose based on AUC. The relevance of these findings to humans is not known.</p><p>&nbsp;</p><p>In the testes, degeneration of the seminiferous epithelium was seen in rats and dogs. The findings were observed at approximately the recommended dose in rats and 3&nbsp;times the recommended dose in dogs (AUC basis). The relevance of these findings to humans is not known.</p><p>&nbsp;</p><p>Findings in the forestomach of mice and rats consisted of squamous epithelial hyperplasia and hyperkeratosis; inflammation; and squamous cell papilloma and carcinoma in studies of 3&nbsp;months or longer in duration. The forestomach of mice and rats does not have a human counterpart.</p><p>&nbsp;</p><p><u>Reproduction toxicity</u></p><p>&nbsp;</p><p>Oral administration of dimethyl fumarate to male rats at 75,&nbsp;250,&nbsp;and 375&nbsp;mg/kg/day prior to and during mating had no effects on male fertility up to the highest dose tested (at least 2&nbsp;times the recommended dose on an AUC basis). Oral administration of dimethyl fumarate to female rats at 25,&nbsp;100,&nbsp;and 250&nbsp;mg/kg/day prior to and during mating, and continuing to Day 7 of&nbsp;gestation, induced reduction in the number of estrous stages per 14&nbsp;days and increased the number of animals with prolonged diestrus at the highest dose tested (11&nbsp;times the recommended dose on an AUC basis). However, these changes did not affect fertility or the number of viable fetuses produced.</p><p>&nbsp;</p><p>Dimethyl fumarate has been shown to cross the placental membrane into fetal blood in rats and rabbits, with ratios of fetal to maternal plasma concentrations of 0.48&nbsp;to 0.64&nbsp;and 0.1&nbsp;respectively. No malformations were observed at any dose of dimethyl fumarate in rats or rabbits. Administration of dimethyl fumarate at oral doses of 25,&nbsp;100,&nbsp;and&nbsp;250&nbsp;mg/kg/day to pregnant rats during the period of organogenesis resulted in maternal adverse effects at 4&nbsp;times the recommended dose on an AUC<sup> </sup>basis, and low fetal weight and delayed ossification (metatarsals and hindlimb phalanges) at 11&nbsp;times the recommended dose on an AUC basis. The lower fetal weight and delayed ossification were considered secondary to maternal toxicity (reduced body weight and food consumption).</p><p>&nbsp;</p><p>Oral administration of dimethyl fumarate at 25,&nbsp;75,&nbsp;and&nbsp;150&nbsp;mg/kg/day to pregnant rabbits during organogenesis had no effect on embryo-fetal development and resulted in reduced maternal body weight at 7&nbsp;times the recommended dose and increased abortion at 16&nbsp;times the recommended dose, on an AUC<sup> </sup>basis.</p><p>&nbsp;</p><p>Oral administration of dimethyl fumarate at 25,&nbsp;100, and&nbsp;250&nbsp;mg/kg/day to rats during pregnancy and lactation resulted in lower body weights in the F1 offspring, and delays in sexual maturation in F1 males at 11&nbsp;times the recommended dose on an AUC basis. There were no effects on fertility in the F1 offspring. The lower offspring body weight was considered secondary to maternal toxicity.</p><p>&nbsp;</p><p>Two toxicity studies in juvenile rats with daily oral administration of dimethyl fumarate from postnatal day (PND)&nbsp;28 through PND&nbsp;90 to 93 (equivalent to approximately 3&nbsp;years and older in humans) revealed similar target organ toxicities in the kidney and forestomach as observed in adult animals. In the first study, dimethyl fumarate did not affect development, neurobehavior or male and female fertility up to the highest dose of 140 mg/kg/day (approximately 4.6&nbsp;times the recommended human dose based on limited AUC data in paediatric patients). Likewise, no effects on male reproductive and accessory organs were observed up to the highest dimethyl fumarate dose of 375&nbsp;mg/kg/day in the second study in male juvenile rats (about 15‑times the putative AUC at the recommended paediatric dose). However, decreased bone mineral content and density in the femur and lumbar vertebrae were evident in male juvenile rats. Bone densitometry changes were also observed in juvenile rats following oral diroximel fumarate administration, another fumaric ester that is metabolised to the same active metabolite monomethyl fumarate in vivo. The NOAEL for the densitometry changes in juvenile rats is approximately 1.5 times the presumptive AUC at the recommended paediatric dose. A relation of the bone effects to lower body weight is possible, but the involvement of a direct effect cannot be excluded. The bone findings are of limited relevance for adult patients. The relevance for paediatric patients is not known.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Capsule contents (enteric-coated microtablets)</u></p><p><u>&nbsp;</u></p><p>Microcrystalline cellulose</p><p>Croscarmellose sodium</p><p>Talc</p><p>Silica, colloidal anhydrous</p><p>Magnesium stearate</p><p>Triethyl citrate</p><p>Methacrylic acid &ndash; methyl methacrylate copolymer (1:1)</p><p>Methacrylic acid &ndash; ethyl acrylate copolymer (1:1) dispersion 30%</p><p>Simeticone</p><p>Sodium laurilsulfate</p><p>Polysorbate 80</p><p>&nbsp;</p><p><u>Capsule shell</u></p><p><u>&nbsp;</u></p><p>Gelatin</p><p>Titanium dioxide (E171)</p><p>Brilliant Blue FCF (E133)</p><p>Yellow iron oxide (E172)</p><p>&nbsp;</p><p><u>Capsule print (black ink)</u></p><p><u>&nbsp;</u></p><p>Shellac</p><p>Potassium hydroxide</p><p>Black iron oxide (E172)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                 4 years

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p>Do not store above 30&ordm;C.</p><p>Keep the blisters in the outer carton in order to protect from light.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>120&nbsp;mg capsules: 14&nbsp;capsules in PVC/PE/PVDC-PVC aluminium blister packs.</p><p>240&nbsp;mg capsules: 56 capsules in PVC/PE/PVDC-PVC aluminium blister packs.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                 Biogen Netherlands B.V.
Prins Mauritslaan 13
1171 LP Badhoevedorp
The Netherlands
Telephone number: +31 (0) 20 5422 000
E-mail: medinfo.netherlands@biogen.com

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                 Jun/2022 
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>